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Colorectal cancer is the fourth most common cause of cancer deaths and the 
high mortality rate is mostly ascribed to liver metastasis. In order to improve 
the clinical management of colorectal cancer metastasis and patient outcome, 
there is currently an urgent need to further the understanding of colorectal 
cancer metastasis, as well as to develop biomarkers with high sensitivity and 
specificity for prognosis and disease monitoring. To address these clinical 
needs, we applied proteomics approaches to identify intracellular and secreted 
proteins differentially expressed in the colon adenocarcinoma cell line HCT-
116 and its metastatic derivative, E1.  
 
In the first part of the study, we compared the intracellular protein profiles of 
HCT-116 and E1 cells using the iTRAQ technology, in order to identify 
potential novel metastatic-related proteins. Drebrin (DBN1), an actin-binding 
protein involved in cytoskeletal remodelling, was found to be overexpressed in 
E1. In comparison to primary colon adenocarcinoma tissue sections, DBN1 
levels were significantly higher in matched lymph node and liver metastases, 
suggesting that DBN1 could be clinically relevant in colorectal cancer 
metastasis. Our findings represent the first time that DBN1 has been shown to 
be involved in colorectal cancer metastasis. 
 
In the second part, we performed an iTRAQ-based comparison between the 
HCT-116 and E1 secretomes to search for novel biomarkers for prognosis and 
disease monitoring. We utilised the hollow fibre culture (HFC) system to 
xi 
 
collect conditioned media (CM) samples from HCT-116 and E1 cells, and also 
showed that the HFC system is a highly attractive and viable alternative for 
CM preparation. Among the differentially secreted proteins identified from the 
E1 secretome, several well-known secreted proteins in colorectal cancer, such 
as GDF15, SPARC and SERPINE1, as well as potentially novel players such 
as PLOD3 and MAN1A1, were identified.  
 
Finally, to delve deeper into the HCT-116 and E1 secretomes in search for 
more low-abundance secreted proteins, we used the multi-lectin affinity 
chromatography (MLAC) approach to enrich for secreted glycoproteins. We 
compared the MLAC-enriched "glycosecretomes" of HCT-116 and E1 using 
the label-free quantitative SWATH-MS technology, and observed that a 
potentially novel secreted protein in colorectal cancer, Laminin subunit β-1 
(LAMB1), was oversecreted in E1 cells. LAMB1 levels were also 
significantly higher in patient serum samples as compared to healthy controls 
when measured using ELISA. ROC analyses indicated that LAMB1 
performed better at discriminating between colorectal cancer patients from 
controls with an AUC of 0.86 (64% sensitivity, 96% specificity), as compared 
to CEA with an AUC of 0.74 (53% sensitivity, 89% specificity). More 
importantly, when LAMB1 is used in combination with CEA, the diagnostic 
performance was further improved, showing an AUC of 0.91 (80% sensitivity, 
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1.1. Colorectal cancer epidemiology 
Colorectal cancer is currently ranked as the third most widespread cancer in 
the world, with over 1.2 million new cases estimated in 2008. The highest 
incidence rates of colorectal cancer occur in developed countries, such as 
Australia, New Zealand, Europe and North America. With more than 608 000 
deaths estimated, colorectal cancer is the fourth most common cause of cancer 
deaths (Jemal et al., 2011). Similar trends are observed in Singapore, where 
colorectal cancer has the highest incidence rate and second most frequent 
cause of death among all cancers in males, and the second most common and 
third in cancer-related deaths among females (Lee et al., 2014). 
 
1.2. Colorectal cancer aetiology 
Colorectal cancer develops from the epithelial cells of the interior lining of the 
large intestines and the rectum. The transformation of normal epithelial cells 
into a benign precursor lesion (adenoma) and subsequently to an 
adenocarcinoma requires a complex interplay of changes at the molecular 
level. Constitutive activation of the Wnt signalling pathway is one of the most 
common genetic aberrations and can be found in about 93% of all colorectal 
cancer cases (de Wit et al., 2013). This is most often caused by mutations in 
the adenomatous polyposis coli (APC) tumour suppressor gene (Cancer 
Genome Atlas, 2012; Kinzler and Vogelstein, 1996). There are also a number 
of other genetic alterations which occur at high frequency in colorectal cancer, 
including activating mutations in KRAS and BRAF, inactivation of TP53, 




Many have also recognised that the introduction of genomic instability is one 
of the major factors that contributes to colorectal cancer malignancy (de Wit et 
al., 2013). Approximately 70% of colorectal carcinomas would display 
chromosomal instability (CIN), where large portions of chromosomes could be 
gained or lost (Pino and Chung, 2010). These changes are usually associated 
with accumulation of mutations in oncogenes and tumour suppressor genes 
which are crucial for colorectal cancer progression (de Wit et al., 2013). 
Another less frequently observed form of genomic instability is microsatellite 
instability (MSI), which can be found in about 15% of colorectal cancer 
patients (Boland and Goel, 2010). In these cases, a defect in the DNA 
mismatch repair mechanism results in accumulation of mutations in 
microsatellites. This leads to frameshift insertions or deletions, which affect 
the transcription of genes involved in DNA repair, cell cycle regulation, 
proliferation and apoptosis (Boland and Goel, 2010; de Wit et al., 2013).  
 
1.3. Colorectal cancer staging systems 
Cancer staging is one of the most crucial elements during diagnosis to define 
the tumour and determine the most appropriate treatment for the patient. In 
colorectal cancer, the two most commonly employed staging systems are the 
Dukes' classification (Dukes, 1932), and the tumour node metastasis (TNM) 
system (maintained collaboratively by the American Joint Committee on 
Cancer and the Union for International Cancer Control). The Dukes' 
classification (Table 1) was originally described in 1932 by a pathologist 
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Cuthbert E. Dukes for the classification for rectal cancers, where three classes, 
A, B and C, were used to describe the extent of rectal tumour spread (Dukes, 
1932). Class C was later divided into C1 and C2, to further differentiate 
between the extent of lymph node metastases (Gabriel et al., 1932). 
Subsequently, the Dukes' classification was extended to include colon tumours 
as well (Simpson and Mayo, 1939). Although not described in the original 
classification, an additional Class D has also become commonly used to 
denote tumours with distant metastasis (Deans et al., 1992). However, the 
Dukes' classification has been complicated by other further modifications, 
resulting in frequent confusion whenever the classification is used (Deans et 
al., 1992).    
 
Table 1. The modified Dukes' classification for colorectal cancer staging 
Modified Dukes' 
classification Description 
A Tumour growth is limited to the mucous membrane and submucosa 







Involvement of lymph nodes 
 
Only regional lymph nodes involved 
 
Metastasis spread to lymph nodes at point of ligature of blood 
vessels 
 







The TNM system for colorectal cancer is largely compatible with the Dukes' 
classification, but is more precise in identifying sub-groups which have 
different prognosis. Colorectal cancer staging using the TNM system 
categorises the tumours based on the depth of tumour invasion into or beyond 
the intestinal walls (T), number of regional lymph nodes involved (N), and the 
presence of distant metastases (M). Combinations of the T, N and M 
characteristics are then used to group patients into different prognostic stages 
(Table 2).  
 
Table 2. The TNM system for colorectal cancer staging 
The tumour node metastasis (TNM) system for staging colorectal cancers, based on the AJCC 
Cancer Staging Handbook, Seventh Edition 
 
Table 2a. Definitions of TNM 
 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into pericolorectal tissues 
T4a Tumour penetrates into surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in one to three regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in two to three regional lymph nodes 
N1c Tumour satellite deposits in subsierose or in non peritonealised tissues 
N2 Metastases in more than four regional lymph nodes  
N2b Metastases in four to six regional lymph nodes 
N2c Metastases in seven or more regional lymph nodes 
 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastases confined to one organ or site (e.g. liver, lung, ovary or non-regional 
node) 





Table 2b. Anatomic stage/Prognostic groups 
 
AJCC/UICC 
staging T N M Dukes 
0 Tis N0 M0 - 
I T1 N0 M0 A 
 T2 N0 M0 A 
IIa T3 N0 M0 B 
IIb T4a N0 M0 B 
IIc T4b N0 M0 B 
IIIa T1-T2 N1/N1c M0 C 
 T1 N2a M0 C 
IIIb T3-T4a N1/N1c M0 C 
 T2-T3 N2a M0 C 
 T1-T2 N2b M0 C 
IIIc T4a N2a M0 C 
 T3-T4a N2b M0 C 
 T4b N1-N2 M0 C 
IVa Any T Any N M1a D 
IVb Any T Any N M1b D 
 
As mentioned earlier, staging plays an important role in colorectal cancer 
disease management as it is the main factor that influences prognosis and 
treatment decisions. The five-year survival rate for patients who present with 
early stage disease (stage I) is more than 90%, while stage II patients would 
have about 70% to 80% survival rates. However, when metastasis to the 
regional lymph nodes have occurred for stage III patients, the five-year 
survival is reduced to 40% to 80%, depending on the number of lymph nodes 
involved. For stage IV patients who have colorectal cancer with distant 
metastasis, the five-year survival rate for patients is only 8% (O'Connell et al., 
2004). From this, it is clear that the high mortality rate in colorectal cancer is 
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due to distant metastasis. Unfortunately, due to the asymptomatic nature of 
colorectal cancer in the early stages, many patients would already present with 
metastatic disease during diagnosis (Paschos and Bird, 2008).  
 
1.4. Clinical needs in colorectal cancer detection and management 
The development from a benign adenoma to a metastatic adenocarcinoma 
progresses through several well-defined stages, and the disease outcome is 
heavily dependent on the stage at which the disease is detected (de Wit et al., 
2013). At every stage of colorectal cancer progression, there are specific 
clinical needs to improve detection and management of the disease (Figure 1). 
 
Figure 1. Clinical needs in colorectal cancer management 
The stage-wise progression of colorectal cancer is shown on the x-axis. On the primary 
y-axis, the time to progression is shown using bars with blue outline, while on the 
secondary y-axis, the five year survival rate is shown using black lines with dots. The 
different clinical needs are shown in orange boxes at the stages of the disease where they 
are most pertinent. Screening biomarkers are required at early stages of the disease where 
clinical intervention is most effective. Prognostic biomarkers are needed from Stage I 
onwards to predict outcome, and similarly so for disease monitoring biomarkers, where 
they are used for monitoring disease recurrence. Novel drug targets are particularly 
important for patients who present with late stage colorectal cancer, in order to reduce the 




5 year survival 
prediction (%)
Normal colon Adenoma Progressive adenoma
Carcinoma














1.4.1. Screening biomarkers: early detection of colorectal cancer 
First of all, since it takes about 17 years for an adenoma to progress to a 
carcinoma (Jones et al., 2008), developing methods for detection of the 
disease at early stages would be one of the most logical approaches to reduce 
mortality in colorectal cancer. Moreover, surgical resection is highly curative 
at early stages of the disease (O'Connell et al., 2004). Currently, the most 
widely employed procedures for colorectal cancer detection are colonoscopy 
and the faecal occult blood test (FOBT), where stools are tested for the 
presence of haemoglobin as an indication of tumour bleeding. However, 
colonoscopy has poor patient compliance as it is expensive and invasive. 
Moreover, even though colonoscopy is generally regarded as the gold standard 
in detection of colorectal cancers and precancerous polyps, it has a miss rate of 
25% for detection of both polyps and adenomas (Leufkens et al., 2012). On 
the other hand, the FOBT is non-invasive, but has poor specificity as the 
presence of blood in the stools could be due to non-tumour lesions. As such, 
there is a need for biomarkers which are directly related to the molecular 
characteristics of the tumour tissue, in order to improve the sensitivity and 
specificity of the detection methods currently available (de Wit et al., 2013).  
 
1.4.2. Biomarkers for prognosis and disease monitoring 
Next, as mentioned earlier, prognosis and treatment decisions for colorectal 
cancer patients are mainly guided by the clinical and/or pathological staging of 
the tumour. Patients who are diagnosed with stage I or II tumours would 
undergo surgical resection only, while stage III patients would be 
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recommended for adjuvant chemotherapy (Labianca et al., 2013). However, 
25-30% of patients would develop metachronous hepatic metastases (Paschos 
and Bird, 2008). Currently, the only biomarker that is clinically used for 
monitoring of colorectal cancer recurrence and metastasis is the 
carcinoembryonic antigen (CEA). Levels of CEA are routinely monitored in 
colorectal cancer patients following surgical resection as high CEA levels 
have been shown to be associated with poor patient outcome (Wang et al., 
1994). However, elevation of CEA can also occur in response to inflammatory 
conditions such as hepatitis and inflammatory bowel disease (van der Schouw 
et al., 1992). Furthermore, there is conflicting data in the literature regarding 
the prognostic utility of CEA (Carpelan-Holmstrom et al., 1996; Carriquiry 
and Pineyro, 1999; Harrison et al., 1997; Moertel et al., 1986). Thus, there is 
also an urgent need for more biomarkers with higher sensitivity and specificity 
to improve prognosis and decision making for colorectal cancer patients. 
 
1.4.3. Novel drug targets for intervention of colorectal cancer 
metastasis 
Even though metastasis is the major contributing factor in colorectal cancer 
mortality, the mechanisms that drive the metastatic transformation remain 
poorly understood. Moreover, as compared to the progression from adenoma 
to carcinoma, the duration required for a carcinoma to further acquire 
metastatic traits appears to be much shorter (approximately 2 years) (Jones et 
al., 2008). Currently, the treatment strategy for patients who present with stage 
IV disease or develop metachronous metastasis is mainly palliative 
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chemotherapy, especially when resection is no longer a suitable option. This is 
typically a "one-size-fits-all" strategy (de Wit et al., 2013), where the 
treatment for most patients consists of a fluoropyrimidine (fluorouracil) in 
various combinations and schedules (Van Cutsem et al., 2010). However, 
these combinatorial fluorouracil therapies are not targeted against metastasis, 
but simply induce cell death through inhibition of RNA and DNA synthesis 
(Longley et al., 2003).  
 
Recently, targeted drug therapies such as monoclonal antibodies against 
vascular endothelial growth factor (VEGF) and epidermal growth factor 
receptor (EGFR) have been recommended to be used in conjunction with 
chemotherapy as they seemed to improve outcome in some colorectal cancer 
patients. These anti-VEGF and anti-EGFR treatments are targeted against 
angiogenesis (Hurwitz et al., 2004) and the MAPK-signalling pathway (Jonker 
et al., 2007) respectively. Unfortunately, there have been some complications 
and restrictions reportedly associated with these therapies. For instance, the 
effectiveness of the anti-EGFR drugs are restricted to KRAS wild-type 
tumours only (Van Cutsem et al., 2010). These further underscore the urgency 
to improve the understanding of the molecular mechanisms involved in 





1.5. Colorectal cancer liver metastasis 
Mortality in colorectal cancer can be mostly ascribed to metastasis. As 
mentioned earlier, the five-year survival prediction of stage IV colorectal 
cancer patients is 8.1%, a drastic reduction from the 44.3% for stage IIIc 
patients (O'Connell et al., 2004). The most prominent form of distant 
metastasis that is observed in colorectal cancer patients is liver metastasis. At 
the point of diagnosis, about 25% of patients would present with hepatic 
metastasis (synchronous metastasis), while a further 25-30% would eventually 
develop secondary tumours in the liver (Paschos and Bird, 2008). Even for 
those patients who are suitable and undergo surgical resection, about 1 in 2 
cases would develop recurrence, and more than 60% of these cases would be 
hepatic-related (de Jong et al., 2009). 
 
The progression from a local adenocarcinoma to metastasis involves a 
complex series of events known as the invasion-metastasis cascade (Valastyan 
and Weinberg, 2011). To generate a clinically detectable neoplasm at 
secondary sites (Figure 2), the epithelial cells in the primary tumour must first 
acquire the ability to invade into the surrounding extracellular matrix (ECM) 
and stromal cells, and then intravasate into the blood vessels supplying the 
primary tumour. Once in the blood circulation, the tumour cells must 
subsequently endure the rigors of transport through the vasculature and evade 
the host immune system, before arresting at a distant organ site. Finally, the 
tumour cells would need to extravasate into the distant tissue, and then survive 






However, although the general metastatic process is understood as such, the 
complex cellular pathways and mechanisms that drive colorectal cancer 
metastasis still remain largely unknown. Therefore, in order to address the 
clinical needs in colorectal cancer metastasis intervention, a more 
comprehensive understanding of the molecular mechanisms that underlie the 
metastatic process is required. However, the players (i.e. proteins) involved in 
these molecular mechanisms hardly act as isolated units, but are 
interconnected in complex and intricate pathways with other proteins and 
Figure 2. The invasion-metastasis cascade 
The invasion-metastasis cascade is a progression of the events that results in the formation 
of clinically detectable metastases from a primary tumour. Metastasising cells must first 
acquire the ability to leave the primary tumour site through local invasion and 
intravasation. They must then be able to survive in the circulation before arresting and 
extravasating at a distant organ site. Finally, the tumour cells must adapt to and colonise 
the foreign environment of the secondary site. Carcinoma cells are shown in red. Figure 
reproduced from Valastyan and Weinberg, 2011, with permission from Cell, Elsevier Inc.  
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cellular components. As such, it would be logical to apply a systems-based 
approach (as opposed to traditional single gene/protein analyses) to more 
effectively elucidate and understand the proteins involved in metastasis. In this 
respect, the comparative analysis of the global protein expression profiles 
using proteomics between metastatic and primary colorectal cancer has been 
shown to be an extremely valuable and appealing approach (Bitarte et al., 
2007). 
 
1.6. Quantitative proteomics technologies 
1.6.1. Gel-based and liquid chromatography (LC)-based quantitative 
proteomics 
Comparative quantitative proteomics involves systemic identification and 
quantitation of the proteins expressed between related biological samples, and 
is most often applied to evaluate global changes in protein abundances that 
occur in response to any physiological events. The traditional workhorse of 
quantitative proteomics is the two-dimensional gel electrophoresis (2-DE) 
method, where all the proteins in a complex protein sample are first 
fractionated according to their respective isoelectric points, and then separated 
according to molecular weight (O'Farrell, 1975). However, there are 
limitations to the 2-DE method, such as inter-gel variation (Righetti et al., 
2004) and poor resolution for highly basic proteins and those smaller than 10 




An alternative to overcome these problems is to switch to liquid 
chromatography (LC)-based platforms to separate the complex protein 
samples. LC-based platforms are advantageous over gel-based methods in that 
the separation of the complex protein samples can be easily automated and 
directly coupled to the mass spectrometer for detection and identification of 
proteins. Moreover, LC separations can be enhanced by performing multi-
dimensional separations through digestion of the proteins into peptides, and 
then exploiting the different chemical interactions between the peptides and 
the stationary phase (Wu et al., 2006). This vastly improves the separation of 
complex biological samples and enables the identification of higher numbers 
of proteins as compared to gel-based methods (Wang and Hanash, 2003).   
 
1.6.2. Stable isotopic labelling strategies for LC-based quantitative 
proteomics 
The introduction of stable isotopic labelling strategies together with high-
throughput multi-dimensional LC platforms was an important factor in driving 
the popularity of comparative quantitative proteomics analyses between 
different biological samples. These strategies involve the incorporation of non-
radioactive stable isotopic tags onto specific amino acids through metabolic or 
chemical means. Metabolic labelling entails the use of culture media 
containing modified essential amino acids (with deuterium, 13C, or 15N) that is 
incorporated in vivo into proteins synthesised by the cells during culture (Ong 
et al., 2002). However, this procedure, known as stable isotope labelling by 
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amino acids in culture (SILAC), can only be performed on in vivo biological 
samples (i.e. cell line and animal models).  
 
On the other hand, chemical labelling techniques can be performed on any 
biological samples, as the labelling is usually performed post-protein isolation 
using isotopic labelling reagents. One such method is the isobaric tags for 
relative and absolute quantitation (iTRAQ) technology. The iTRAQ approach 
was originally based on four isobaric (same mass) reagents that are covalently 
attached to the N-termini and lysine side chains of post-tryptic digest peptides 
(Ross et al., 2004). Each of the iTRAQ reagents consists of a reporter group, a 
balance group and the amine-reactive group. The reporter groups of the four 
isobaric reagents have masses ranging from 114 to 117 m/z, and the balance 
groups have varying masses to maintain the same overall mass for all four 
reagents.  
 
The typical iTRAQ labelling workflow involves the simultaneous tryptic 
digestion of up to four different samples followed by labelling of the four 
samples with each of the four isobaric iTRAQ reagents. The resultant iTRAQ-
derivatised peptides can then be pooled and analysed in a single LC-MS 
experiment. During MS, because of the isobaric nature of the iTRAQ reagents, 
identical peptides from different samples (labelled with different iTRAQ 
reagents) are indistinguishable from each other because they will have the 
same precursor m/z. Subsequently, during collision induced dissociation (CID) 
of the precursor ions in MSMS mode, the reporter groups are released from 
the peptides and generate strong peak signals which can then be analysed to 
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infer the relative abundance of the labelled peptides. Interestingly, the iTRAQ 
reagents have been shown to enhance the fragmentation efficiency of the 
labelled peptides, leading to improved signals from the daughter ions and 
overall better sequence coverage (Hardt et al., 2005). Moreover, the iTRAQ 
technology has been shown to be complementary to gel-based techniques in 
terms of protein identification, but is much more sensitive (Wu et al., 2006). 
Currently, the iTRAQ technology has been improved for use of up to eight 
isobaric reagents (ranging from 113 to 121 m/z, excluding 120 m/z). Therefore, 
this allows for concurrent analysis of up to eight different biological samples 
in a single LC-MS/MS experiment, enabling iTRAQ to remain as one of the 
most powerful tools for LC-based quantitative proteomics.   
 
1.6.3. SWATH-MS - a label-free alternative for quantitative 
proteomics 
Although labelling-based strategies are known to be more accurate in protein 
quantitation, they have several restrictions, which include limited number of 
samples analysable in a single run, requiring expensive isotope labels and 
complex sample preparations (Neilson et al., 2011; Patel et al., 2009). 
Therefore, there is increasing interest recently in exploring quantitative 
proteomics strategies which do not require any stable isotopic labelling (i.e. 
label-free quantitative proteomics). Currently, there are two different 
approaches for label-free quantitation: area under the curve (AUC) 
measurement and spectral counting (Neilson et al., 2011). AUC measurement, 
also known as ion counts, uses the integrative measurement of the precursor 
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ion abundance at a specific retention time as a reflection of the respective 
peptide abundance (Podwojski et al., 2010). In contrast, spectral counting 
involves quantitation by counting the number of MSMS spectra assigned to a 
particular peptide, and is based on the premise that more abundant peptides 
will have higher tendency to be selected for fragmentation, and therefore 
should produce more MSMS spectra (Liu et al., 2004).    
 
SWATH-MS is an AUC measurement-based label-free quantitation method 
that was recently developed. Conceptually, SWATH-MS is closer to selected 
reaction monitoring (SRM, also known as multiple reaction monitoring or 
MRM) in targeted proteomics. SRM involves the monitoring of a pre-
determined pairs of peptide precursors and fragment ions (known as 
transitions). Quantitation is performed by measuring the intensities of the 
fragment ions, and is therefore essentially AUC measurement-based (Neilson 
et al., 2011). Although highly accurate and reproducible, SRM is limited by 
the number of proteins that can be analysed in a single LC-MS experiment. 
Therefore, SRM is most often used as a validation tool for both label-free and 
labelled quantitative proteomics experiments.  
 
SWATH-MS overcomes the limitations of SRM by merging the high 
throughput protein identification capabilities of discovery proteomics with the 
reproducible and accurate quantitation of targeted proteomics (Gillet et al., 
2012). This is achieved by using an unbiased data independent acquisition 
(DIA) method, where all precursor ions within a specific mass window are 
fragmented for MSMS analysis (Figure 3). This is unlike the traditional data 
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dependent acquisition (DDA) method used in discovery proteomics, where the 




Figure 3. Data-dependent acquisition (DDA) vs. data-independent acquisition (DIA) 
In DDA, the most abundant precursors are selected by the mass spectrometer for 
fragmentation, and the resultant spectra is composed of the fragment ions of the selected 
precursor peptide only. However, in DIA, a pre-determined mass isolation window is 
specified, and all precursors within this mass range are allowed to pass through for 
fragmentation. Thus, the resultant spectra is a recording of all fragment ions that are 
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Specifically, the SWATH-MS DIA workflow involves the repeated and 
continuous acquisition of fragment ion spectra from all precursor ions within 
sequential series of 25 Da isolation windows throughout a specified mass 
range of 350 to 1250 m/z (termed as "swaths", see Figure 4). The resultant 
output is therefore composite spectra of all the fragment ions that are derived 
from all the precursor ions within each swath. In order to identify peptides that 
are present within these composite spectra, a spectra ion library that contains 
peptide identities with their corresponding fragment ion information would be 
required, and is usually generated by traditional DDA and database searching. 
Quantitation is then performed by AUC measurement of the highest intensity 
fragment ion signals. Due to the high resolution of the quadrupole time-of-
flight (QqTOF) instrument, it has been shown that the accuracy and 
reproducibility of SWATH-MS quantitative analysis is comparable to that of 
SRM, which is considered as the gold standard in quantitative mass 
spectrometry analysis (Liu et al., 2013). Considering these, SWATH-MS 
could become a powerful label-free alternative for performing unbiased 






Figure 4. The SWATH-MS workflow 
(A) SWATH-MS data-independent acquisition (DIA) consists of the continuous 
acquisition of high resolution fragment ion spectra across the entire chromatographic 
elution time range (retention time) by repeatedly stepping through distinct precursor 
isolation windows of 25 Da width (black double arrow) throughout the specified mass 
range of 350 – 1250 m/z. The series of isolation windows acquired for a specific mass 
range (e.g. 400 – 425 m/z) across the retention time range is denoted as a “swath” 
(highlighted in red) (Gillet et al., 2012). The result of the SWATH-MS acquisition are 
spectra that are composite of all fragment ions derived from the precursors within each 
swath. (B) In order to identify the peptides within the spectra, traditional data-dependent 
acquisition (DDA) is used to generate a spectra ion library containing fragment ion spectra 
with corresponding peptide identity information. (C) Peptide identification is performed 
by matching the fragment ion spectra from the SWATH-MS analysis (top, blue) against 
that of the spectra ion library (bottom, purple), while (D) quantitation is performed by 
extracting the highest intensity fragment ions and overlaying them in a SRM-like extracted 
ion chromatogram (XIC). Peptide abundance is then estimated by AUC measurement of 




1.7. Addressing clinical needs in management of colorectal cancer 
metastasis using proteomics  
1.7.1. Identification of novel intracellular proteins involved in 
colorectal cancer metastasis using comparative quantitative 
proteomics 
Proteomics approaches are ideal for discovering new and unexpected protein 
relationships because of its unbiased nature. As such, comparative quantitative 
proteomics analyses between primary and metastatic colorectal cancer will be 
highly useful for elucidating novel changes in protein expression levels that 
could be related to metastasis. Although comparing tissue extracts from 
synchronous or metachronous liver metastasis with the primary tumour would 
be the ideal case study, such samples are often difficult to obtain, and yet the 
intrinsic biological heterogeneity among individual patients would mean that 
larger samples numbers are required (Chen and Yates, 2007; Chen et al., 
2006). Cell lines, on the other hand, are renewable resources and highly 
suitable for the large amount of samples required for proteomic analyses 
(Chen and Yates, 2007). Furthermore, they are mostly homogenous and easily 
manipulated for downstream functional studies. 
 
Various groups around the world have reported utilising comparative 
proteomics approaches on either cell lines or patient tissues to study colorectal 
cancer liver metastasis. Using comparative 2-DE analyses, a number of 
interesting targets have been identified, such as the mitochondrial F0F1-ATP 
synthase (Chang et al., 2007), hnRNPA1 (Ma et al., 2009), RhoGDI (Zhao et 
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al., 2008), HMGB1 (Liu et al., 2007; Zhao et al., 2007) and HSP27 (Liu et al., 
2007; Pei et al., 2007; Zhao et al., 2007).  
 
Considering the advantages of LC-based quantitative proteomics approaches 
over gel-based methods mentioned earlier, iTRAQ would be a highly 
appealing approach to discover more novel proteins involved in colorectal 
cancer metastasis. Currently, there have been several reports which have 
utilised the iTRAQ technology to discover diagnostic biomarkers in colorectal 
cancer tissues (Besson et al., 2011; Fan et al., 2012) and plasma samples 
(Zhang et al., 2012a), as well as investigating the effects of butyrate treatment 
(Tan et al., 2008) and a novel phosphoinositide-3 kinase inhibitor drug 
(Mallawaaratchy et al., 2012) on colorectal cancer cells. However, only Ghosh 
and colleagues (2011) performed an iTRAQ-based comparison between the 
primary colon cancer cell line SW480 and its lymph node metastatic variant 
SW620 in search of proteins involved in colorectal cancer metastasis. It should 
be additionally noted that the abovementioned studies in the previous 
paragraph only utilised the SW480 and SW620 pair of cell lines as well, and 
thus may potentially be introducing a biased perception of the colorectal 
cancer metastasis mechanism (Schaaij-Visser et al., 2013). As such, it will be 
useful to examine other isogenic colorectal cancer cell lines with different 
metastatic potentials to gain a different perspective on other novel proteins 




1.7.2. Identification of serological biomarkers by analysing the 
colorectal cancer secretome  
In clinical screening, blood-based assays are most commonly employed 
because of their simplicity and non-invasiveness. Unfortunately, biomarker 
discovery using patient blood samples can be extremely challenging due to the 
broad dynamic range of serum and plasma protein concentrations. The 
presence of the high abundance proteins, such as albumin, haptoglobin, 
transferrins and immunoglobins, hinders the detection of tumour-specific 
biomarkers, which are usually at very low concentration ranges of nanograms 
per millilitre (Zhang and Chan, 2007). Consequently, there is increasing 
interest in proteomics analyses of other proximal biological fluids and in 
particular, the “secretome”: proteins secreted from cancer tissue specimens 
and cell lines.  
 
The term "secretome" was originally used by Tjalsma and colleagues (2000) 
to describe the total proteins that are released by a cell, tissue or organism. 
These secreted proteins constitute approximately 10-15% of the total proteins 
encoded by the human genome and are known to be involved in important 
physiological processes including immune defense, blood coagulation, matrix 
remodelling and cell signalling (Karagiannis et al., 2010). Proteins can be 
released into the extracellular space through two mechanisms: the classical 
secretory pathway and the non-classical secretory pathways. In the classical 
secretory pathway, proteins targeted for extracellular release are synthesised as 
protein precursors which usually contain signal peptides located at the N-
terminus. These signal peptides direct the proteins to the rough endoplasmic 
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reticulum (ER) and subsequently to the Golgi apparatus, following which the 
proteins would then be released into the extracellular environment in Golgi-
derived secretory vesicles. Alternatively, proteins can be exported through 
ER/Golgi-independent mechanisms which are also known as the non-classical 
secretory pathways. In these non-classical secretory pathways, proteins may 
be exported by targeting endosomes recycling back to the plasma membrane, 
directly translocating across the plasma membrane, or through exosomal 
secretion (Nickel, 2003). Exosomes are intralumenal vesicles (ILVs) which 
are formed by inward budding from the limiting membrane of multivesicular 
bodies (MVBs). During the formation process, some cytosolic proteins may be 
incorporated into the invaginating membrane and become engulfed in the 
ILVs. As a result, when a MVB eventually fuses with the plasma membrane, 
the ILVs within are released extracellularly together with their cargo of 
cytosolic proteins (Simpson et al., 2008).   
 
The neoplasm is by no means a stand-alone entity. Tumour cells constantly 
interact with their extracellular environment to create favourable conditions 
for tumour progression, such as inducing angiogenesis or degrading the 
extracellular matrix to facilitate metastasis. These interactions are mediated by 
a variety of proteins secreted by the tumour cells, including growth factors, 
chemokines, cytokines, adhesion molecules, proteases and shed receptors. In 
the same way, surrounding stromal cells are also recruited by tumour cells to 
actively release proteins which further the progression of the neoplasia 
(Karagiannis, 2010). Thus, the cancer secretome can be described as 
constituting of proteins released from cancer-associated stromal cells, as well 
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as all proteins that are secreted by cancer cells through classical or non-
classical secretory pathways, or shed from the cell surface (Makridakis and 
Vlahou, 2010). Since these secreted proteins are released into the extracellular 
environment, they have the highest likelihood of entering the blood circulation 
and thus present a highly promising source for serological biomarker 
discovery. 
 
By definition, the cancer secretome would include all the secreted proteins that 
are found in the tissue interstitial fluids and other proximal biological fluids. 
However, it is now more commonly associated with the conditioned media 
(CM) samples collected from cancer cell lines (Karagiannis et al., 2010), as 
many cancer secretome discovery studies would choose to analyse CM 
samples due to the challenges associated with using biological fluids. A couple 
of previous studies have successfully identified potential serological 
biomarkers from CM samples of colorectal cancer cell lines. Wu and 
colleagues (2008) analysed the CM from 21 different cell lines across 12 
cancer types and found that secretion of CRMP2 (collapsin response mediator 
protein-2) was specific to colorectal cancer. They further showed that levels of 
plasma CRMP2 were significantly higher in colorectal cancer patients and 
thus proposed that CRMP2 could be a potential colorectal cancer-specific 
diagnostic marker. The Schwarte-Waldhoff group discovered that high levels 
of sE-cadherin (soluble E-cadherin) was secreted from SW620, HT29 and 
SW948 cells (Diehl et al., 2007) and subsequently showed that serum sE-
cadherin was significantly higher in patients with Stage III and IV carcinomas 
(Weiss et al., 2011). In a similar study, Xue and colleagues (2010) compared 
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the CM from SW480 and SW620 cells and found that serum TFF3 (trefoil 
factor 3) and GDF15 (growth/differentiation factor 15) levels could be used 
for diagnostic discrimination for patients with colorectal cancer lymph node 
metastasis. These studies illustrate the potential of using colorectal cancer cell 
line CM for discovering potential serological biomarkers for colorectal cancer. 
 
However, one challenge of using CM samples for biomarker discovery is that 
the concentration of the secreted proteins is usually very low, due to the high 
dilution from the culture media. As such, in order to obtain sufficient starting 
material for proteomics analyses, typical CM preparation procedures would 
involve the culture of the cells in multiple culture flasks, followed by 
collecting of the CM samples and concentrating the secreted proteins into a 
smaller volume. Precipitation and ultrafiltration are two classical 
concentration methods routinely used in secretome studies. Precipitation using 
trichloroacetic acid (TCA) is an effective procedure, but often results in poor 
yield, especially during resolubilisation. Ultrafiltration using molecular weight 
cut-off columns is a simpler method, but is time-consuming and loss of low-
molecular weight proteins may occur (Mbeunkui et al., 2006). Another 
challenge associated with using CM samples is that detection of secreted 
proteins may be confounded by the presence of intracellular proteins, which 
are released during cell lysis. This is exacerbated by the usage of serum-free 
media during CM sample preparation. However, this is almost unavoidable as 
serum proteins would interfere with detection of secreted proteins, because of 
their high abundances and sequence homologies with secreted proteins 




In a novel breakthrough to circumvent the above issues, the Liao group 
proposed the use of the commercially available hollow fibre culture (HFC) 
system to simultaneously collect and concentrate secreted proteins from 
cultured cells (Chiu et al., 2013; Wu et al., 2009). The HFC system consists of 
a hollow fibre cartridge coupled to an oxygenator coil, a culture media 
reservoir and a perfusion pump (Figure 5). The cells are cultured within the 
cartridge containing a total of 2800 hollow fibres, providing a surface area 
sufficient to support the adherence and growth of up to 109 cells. The culture 
media is supplied into the extra-capillary space (ECS) of the cartridge through 
the intralumen space in the hollow fibres and continuously recirculated 
throughout the system. The hollow fibres have a molecular weight cut-off of 5 
kDa, which allows for exchange of nutrients and waste material from the ECS, 
but retains cells and secreted proteins larger than 5 kDa within the ECS. Since 
the volume of the ECS is only 15 ml, the HFC system enriches for secreted 
proteins in CM samples by facilitating high-density cell culture while retaining 
secreted proteins in a small media volume. Moreover, due to the large surface 
area for cell growth and dynamic removal of waste, cell lysis rates could be 
reduced significantly, thus lessening the extent of intracellular protein 
contamination in the CM samples. Although the HFC system appears to be a 
highly appealing method for preparation of CM, there are only a few studies 
which have utilised it thus far, such as in the secretome analyses of 
nasopharyngeal carcinoma (Chang et al., 2009; Wu et al., 2009), 
hepatocellular carcinoma (Wen et al., 2011), non-small cell lung cancer 
(Chang et al., 2012) and cholangiocarcinoma (Weeraphan et al., 2012). 
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Therefore, given the practical usefulness of the HFC system, it could be worth 
applying the HFC system for collection of CM samples from colorectal cancer 






Figure 5. The hollow fibre culture (HFC) system 
(A) Schematic diagram of the HFC system setup. Culture media is circulated from the 
media reservoir throughout the entire setup in a continuous loop by the action of the dual 
peristaltic pump. The dual peristaltic pump allows for the simultaneous culture of two 
hollow fibre cartridges. Before entering the hollow fibre cartridge, the culture media is 
equilibrated to the air composition and temperature of the incubator through the 
oxygenator coil. (B) Longitudinal section of the hollow fibre cartridge. The hollow fibres 
are sealed within the cartridge and the culture media would flow through the intralumen 
space of the hollow fibres. Cells would be inoculated into the system through one of the 
side ports and adhere onto the exterior of the hollow fibres. (C) Transverse section of the 
hollow fibre cartridge. Due to the 5 kDa MWCO of the hollow fibres, the culture media 
can freely exchange between the hollow fibres and the extracapillary space (ECS). 




1.7.3. Delving deeper into the "glycosecretome" - enriching for 
differentially secreted glycoproteins between HCT-116 and E1 
There is also an increasing interest in the enrichment of secreted proteins from 
the CM in order to enhance the detection of more low abundance tumour 
specific biomarkers. Various strategies for enrichment of secreted proteins 
have been introduced, including the use of resin-bound hexapeptide libraries 
(Colzani et al., 2009) and metabolic labelling coupled with click chemistry 
(Eichelbaum et al., 2012). Among these, one of the most commonly employed 
approaches in secretome studies is glycoprotein enrichment.   
 
Glycosylation is one of the most prevalent and biologically important post-
translational modifications in proteins. Protein glycosylation most commonly 
occurs on either asparagine residues (N-linked glycosylation), or serine or 
threonine resisdues (O-linked glycosylation). As the majority of serum 
proteins, as well as secreted proteins, are glycoyslated, targeting of the 
carbohydrate moieties could be used as a method to enrich for secreted 
glycoproteins, as well as eliminate intracellular contamination (Ahn et al., 
2010; Zhang et al., 2012b). Many different techniques for glycoprotein 
enrichment have been developed, but the hydrazide chemistry and lectin 
capture methods are most widely employed (Pan et al., 2011). 
 
The use of hydrazide chemistry to enrich for glycoproteins was first described 
by Zhang and colleagues (2003) as a means to selectively capture N-linked 
glycoproteins in human serum. The carbohydrate moieties on glycoproteins 
are first oxidised to form aldehydes, which are subsequently covalently bound 
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to hydrazide groups immobilised on resins. In theory, this approach should be 
able to capture most of the glycoproteins present in any biological sample. 
However, the caveat lies in the limitation of methods available to release the 
bound glycoproteins or glycopeptides (Pan et al., 2011). For N-linked 
glycoproteins, this is easily accomplished by using the peptide-N-glycosidase 
F (PNGase F) enzyme, which specifically cleaves between the oligosaccharide 
group and the asparagine residue. Unfortunately, for O-linked glycoproteins, 
there are no straightforward approaches for releasing the proteins from the 
resin. The oligosaccharide chain must be sequentially cleaved using a series of 
exoglycosidases until the core structure can be removed using either O-
glycosidase or chemical methods, such as β-elimination (Wei and Li, 2009).  
 
On the other hand, the lectin capture strategy, or lectin affinity 
chromatography, is more straightforward, flexible and cost-effective (Wei and 
Li, 2009). Lectins are proteins that have high affinity for carbohydrate 
moieties, and different lectins can selectively bind to different sets of 
oligosaccharide epitopes (some may have overlapping affinities). Lectin 
affinity enrichment experiments are usually designed with the desired lectin 
immobilised on solid supports such as agarose or silica in varying 
chromatographic formats, and bound glyoproteins are easily eluted using 
either low pH or competitive displacement with inhibitory sugars (Fanayan et 
al., 2012; Wei and Li, 2009). However, a major drawback of lectin affinity 
chromatography is that no single lectin can comprehensively cover the entire 




A simple solution to this problem was proposed by Yang and Hancock (2004). 
Instead of using a single lectin, the authors showed that a mixture of different 
lectins in a single column (termed multi-lectin affinity chromatography, 
MLAC) could provide a more complete enrichment of glycoproteins from 
human serum. This was achieved by combining the different affinities of three 
lectins: Concanavalin A (Con A), wheat germ agglutinin (WGA) and Jacalin 
(JAC). Con A has high affinity for α-mannose structures, WGA binds to N-
acetylglucosamine (GlcNAc) and sialic acid residues, while JAC recognises 
N-acetylgalactosamine (GalNAc) moieties (West and Goldring, 2004). Since 
most N-glycans have a core structure of two GlcNAc residues followed by 
three mannosyl residues, these structures will be targeted by Con A and WGA 
(Figure 6). On the other hand, JAC has a high affinity for GalNAc, which is a 
common feature in O-glycan core structures. Additionally, many O-glycans 
also terminate with sialic acid (Pahlsson et al., 1994). Therefore, the 
combination of these three lectins would, in theory, be able to capture a large 






Figure 6. Overview of glycan structures targeted by MLAC 
All N-glycans have a common core consisting of Man3GlcNAc2 attached to asparagine (in 
a consensus sequence of NX[ST]), and are classified according to three types: high 
mannose, where only mannose residues are attached to the core; complex, where a variety 
of diverse monosaccharides are attached to the core; and hybrid, where only mannose 
residues are present on one arm of the core, and other types of monosaccharides can be 
found on the other arm (Stanley et al., 2009). O-glycans are linked through GalNAc 
residues to the –OH groups on serines and threonines. There are four main types of core 
structures in O-glycans which are more commonly observed, which are delineated by the 
red dotted boxes (Brockhausen et al., 2009). Among the three different lectins used in 
MLAC, Con A targets high mannose type structures, WGA has high affinity for the 
GlcNAc residues in the core structures in N-glycans, while JAC binds to the GalNAc 
residues common in the cores of O-glycans. Moreover, WGA can also recognise sialic 
acid residues, which can be found in complex and hybrid N-glycans, as well as in the 
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Moreover, when multiple lectins are mixed together, their binding affinities 
are enhanced considerably as compared to individual lectins. This is due to a 
phenomenon known as the glycoside cluster effect, where the clustering of 
both lectins and carbohydrates have been shown to lead to increased binding 
affinities (Lundquist and Toone, 2002). Because of this effect, it is possible to 
use MLAC to enrich for even mid- to low-abundance glycoproteins from 
biological samples (Taylor et al., 2009). 
 
There have been a number of studies which have reported the use of MLAC 
for glycoprotein enrichment for discovery of cancer biomarkers, and 
demonstrated that MLAC could be effectively used on various biological 
samples. For instance, MLAC can be used directly with serum samples to 
identify serum glycoproteins associated with breast (Yang et al., 2006) and 
lung cancer (Heo et al., 2007), or the serum samples could be immuno-
depleted first before MLAC enrichment to enhance the identification of low 
abundance proteins (Zeng et al., 2011). MLAC can also be applied on tissue 
samples, as shown by Na and colleagues (2009), who identified 
carboxylesterase 1 as a potential serological biomarker for hepatocellular 
carcinoma. Qi and colleagues (2014) similarly used MLAC enrichment on 
HCC tissues and found that pro-Cathepsin D was elevated in HCC patients. 
Applying MLAC on CM cultured from tumour tissue explants, Yao and 
colleagues (2012) discovered that EFEMP2 could be used as a biomarker for 
early detection for colorectal cancer. Although MLAC has been successfully 
utilised on these different kinds of samples, there are as yet no studies which 
have applied it on cell line CM. As such, it might be useful to explore the 
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applicability of MLAC on enriching for secreted glycoproteins from CM 
collected from colorectal cancer cell lines.  
 
1.8. Aim of our study  
1.8.1. Modelling colorectal cancer liver metastasis with the isogenic 
HCT-116 and E1 cell lines 
Hepatic metastasis is one of the major factors that contributes to the high 
mortality rate in colorectal cancer. To improve patient outcome, there is an 
urgent need to identify novel proteins involved colorectal cancer metastasis, as 
well as to discover biomarkers with better sensitivities and specificities for 
prognosis and monitoring. Therefore, in our study, we utilised an isogenic pair 
of cell lines consisting of the poorly metastatic colon adenocarcinoma cell line 
HCT-116 and its liver metastatic derivative, E1, to model for colorectal cancer 
liver metastasis. The E1 cell line was generated by in vivo passaging of HCT-
116 cells and generation of liver metastasis in athymic nude mice (Tay et al., 
2010). E1 cells were shown to display features characteristic of epithelial-
mesenchymal transition, and possess increased motility and invasiveness as 
compared to the parental HCT-116 cells. Moreover, karyotype analyses on the 
E1 cells showed similar non-reciprocal translocations as those observed in the 
parental HCT-116 cell line, indicating that their genetic backgrounds were 
largely similar (Tay et al., 2010). Therefore, we reasoned that any differences 
that are observed in a comparison between the protein expression profiles of 




1.8.2. A tripartite approach to address clinical needs in colorectal 
cancer management using proteomics 
The aim of our study was to apply proteomics approaches in addressing the 
clinical needs in colorectal cancer metastasis management in three ways 
(summarised in Figure 7). First, to uncover novel proteins involved in 
colorectal cancer liver metastasis, we used the iTRAQ technology to compare 
between the HCT-116 and E1 intracellular proteomes, in order to identify 
proteins that were differentially expressed in E1. Second, to identify more 
sensitive and specific biomarkers for prognosis and monitoring, we analysed 
the secretomes of HCT-116 and E1 cells in search of metastasis-related 
secreted proteins which could be translated into serological biomarkers. Using 
the HFC system for preparation of CM samples from HCT-116 and E1 cells, 
we subsequently performed an iTRAQ-based comparison between the HCT-
116 and E1 secretomes to identify differentially secreted proteins in E1 cells. 
We also explored here the applicability of the SWATH-MS technology as a 
MS-based tool for large-scale verification of the iTRAQ analysis of the HCT-
116 and E1 secretomes. Finally, in order to fractionate the CM to enhance the 
detection of more low abundance secreted proteins, we enriched for secreted 
glycoproteins (glycosecretome) in the HCT-116 and E1 cell lines using the 
MLAC approach. After the MLAC enrichment, we then compared between 
the HCT-116 and E1 glycosecretomes using SWATH-MS as an unbiased 
label-free quantitative proteomics technology, in search for differentially 
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Figure 7. A tripartite proteomics approach to address clinical needs in colorectal 
cancer management 
The aims of our study were threefold. First, intracellular proteins were extracted from 
HCT-116 and E1 cells and were compared using the iTRAQ technology to identify 
differentially expressed proteins in E1. Some of these could be potentially novel 
metastasis-related proteins. Second, secreted proteins from HCT-116 and E1 cells were 
collected from their respective CM samples and compared using the iTRAQ technology. 
Large-scale verification of the iTRAQ data was performed using the SWATH-MS 
technology as a targeted quantitative proteomics approach. Finally, we enriched for 
secreted glycoproteins from HCT-116 and E1 cells using the MLAC approach, in search 
for more low-abundance secreted proteins. An unbiased label-free SWATH-MS-based 
quantitative comparison between the HCT-116 and E1 glycosecretomes was performed. 
The second and third aims of our study were targeted towards the identification of 





























2.1. Cell lines 
The HCT-116 human colorectal adenocarcinoma cell line was obtained from 
the American Type Culture Collection (ATCC, Rockville, MD). The 
metastatic derivative E1 cell line was a kind gift from Professor SC Hooi 
(Department of Physiology, Yong Loo Lin School of Medicine, National 
University of Singapore). The two cell lines were cultured in McCoy’s 5A 
media (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine 
serum (Life Technologies Gibco, Carlsbad, CA), in a humidified incubator 
(37oC, 5% CO2).  
 
2.2. HFC system cell culture and collection of CM 
HCT-116 and E1 cells were initially cultured in McCoy’s 5A media 
supplemented with 10% FBS in a humidified incubator (37oC, 5% CO2). Cells 
were harvested using trypsin, and the cell number and viability was 
determined using the trypan blue exclusion test. Harvested cells were 
resuspended in McCoy’s 5A media and subsequently inoculated into a HFC 
system cartridge (C2008, FiberCell Systems Inc, Frederick, MD). Before 
inoculation, the HFC cartridge was pre-cultured twice with sterile PBS, and 
then twice with McCoy’s 5A media supplemented with 10% FBS. The 
FiberCell Systems Duet Pump (FiberCell Systems Inc) was used for 
simultaneous control of the circulation of two HFC cartridges in a humidified 




HCT-116 and E1 cells were inoculated into separate HFC cartridges. After 
allowing the cells to adhere, the reservoir media was substituted with Hyclone 
serum-free McCoy’s 5A media without phenol red (Thermo Scientific 
HyClone, South Logan UT) supplemented with CDM-HD serum replacement 
(FiberCell Systems Inc). In addition, the extra capillary space (ECS) of the 
cartridges was flushed with 20 ml of HyClone serum replacement media 
multiple times until all traces of serum proteins were removed as determined 
using SDS-PAGE.  
 
The cells were further incubated in the HyClone serum replacement media for 
24 h before commencing daily collection of the CM samples. Aliquots of 
media were aspirated from the reservoir daily and glucose concentrations in 
the aliquots were measured using Accu-Check Advantage Meter Kit (Roche 
Diagnostics, Basel, Switzerland). The glucose consumption rates of the cells 
were used as an indicator of cell growth. The media reservoir was replaced 
with a fresh bottle once the glucose concentration was reduced by 50%.  
 
Each of the CM sample collected from the ECS was centrifuged at 350 x g for 
5 min at 15°C, and the supernatant was filtered using a 0.2 μm filter (Sartorius 
Stedim Biotech S.A., Aubagne Cedex, France). The filtrate was then 
concentrated using the Amicon Ultra-15 Centrifugal Filter Device (5 kDa 
MWCO; Millipore, Bedford/Billerica, MA). The concentrated CM samples 
were further subjected to buffer exchange on the same centrifugal filter device 
by washing thrice with 0.5 M triethylammonium bicarbonate (TEAB; Sigma 
Aldrich, St Louis, MO). Six CM samples per cell line were pooled. Whole cell 
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lysate samples were obtained from the respective cells cultured in the HFC 
cartridges by boiling in 0.5 M TEAB and 1% (w/v) SDS buffer at 100°C for 
10 min. 
 
2.3. Multi-lectin affinity chromatography (MLAC) enrichment 
CM samples were prepared in a similar manner as described in the above 
section. The multi-lectin columns were prepared by mixing 1.0 ml each of 
agarose-bound ConA, WGA, and Jacalin (Vector Laboratories, Burlingame, 
CA) in empty PD-10 disposable columns (Amersham Biosciences, Piscataway, 
NJ). The columns were first equilibrated twice with 10 ml of loading buffer 
(20 mmol/L Tris, 0.15 mol/L NaCl, 1 mmol/L Mn2+, and 1 mmol/L Ca2+, pH 
7.4). HCT-116 and E1 CM samples, each containing 1 mg of protein, were 
diluted with loading buffer to 2 ml before loading into the MLAC column. The 
columns were then incubated overnight at 4oC with rocking to maximise 
glycoprotein binding. The unbound proteins were collected using 10 ml of 
loading buffer, followed by three washes using 10 ml of loading buffer each.  
Subsequently, the bound glycoproteins were released using 10 ml of elution 
buffer (20 mmol/L Tris, 0.5 mol/L NaCl, 0.17 mol/L methyl-α-D-
mannopyranoside, 0.17mol/L N-acetylglucosamine and 0.27 mol/L galactose, 
pH 7.4). The eluted glycoprotein fractions were then concentrated using 




2.4. iTRAQ labelling 
2.4.1. iTRAQ labelling of whole cell lysate samples 
Four biological replicates each of HCT-116 and E1 cells were harvested. The 
cells were lysed in a buffer consisting of 0.5 M TEAB and 1% SDS with 
boiling at 100oC for 10 min. The resulting cell lysates were then centrifuged at 
17,000 x g for 1 hr at 15oC to remove cell debris. Protein quantitation was 
performed using the Coomassie Plus Protein Assay Reagent kit (Pierce 
Biotechnology) following the manufacturer’s instructions. The samples were 
labelled with iTRAQ tags according to the manufacturer’s recommendations 
(AB SCIEX, Foster City, CA). Briefly, 50 µg of protein was subjected to 
reduction using 5 mM tris-(2-carboxyethyl)-phosphine (TCEP) at 60oC for 1 
hr. This was followed by alkylation of cysteine residues with 10 mM methyl 
methane-thiosulfonate (MMTS) at room temperature for 10 min. Each of the 
samples was subsequently diluted to 0.05% SDS before digestion with trypsin 
(Trypsin with CaCl2, AB SCIEX) at 37oC for 16 hr. The resulting tryptic 
digests were labelled for 2 hr with the iTRAQ 8-plex reagents in the following 
order: Tag113 - Tag116 to four biological replicates of HCT-116, and Tag117 -
Tag121 to four biological replicates of E1. These eight iTRAQ-derivatised 
samples were then pooled. Interfering substances were removed using a 
cation-exchange cartridge system (AB SCIEX) according to the 
manufacturer’s instructions. The ion-exchange eluate was desalted using a 
Sep-Pak C18 cartridge (Waters, Milford, MA), and subsequently lyophilised 
and reconstituted in 5 mM KH2PO4 in 5% acetonitrile (pH 3) for two-




2.4.2. iTRAQ labelling of whole secretome samples 
iTRAQ labelling was performed similar to the previous section. The tryptic 
digests were labelled with the iTRAQ 8-plex reagents in the following order: 
Tag113 and Tag117: biological replicates of HCT-116 CM samples; Tag114 and 
Tag118: biological replicates of E1 CM samples; Tag115 and Tag119: biological 
replicates of HCT-116 lysate samples; and, Tag116 and Tag121: biological 
replicates of E1 lysate samples. The lyophilized iTRAQ-labelled peptide 
mixture was reconstituted in 5% acetonitrile (ACN) with 0.05% formic acid 
(FA) for 2-D LC.  
 
2.5. LC-MS analysis 
2.5.1. 2-D LC - MALDI-TOF/TOF analysis for cell lysate samples 
The iTRAQ-labelled peptide mixture was separated by 2-D LC consisting of 
strong cation exchange (SCX) followed by reversed phase (RP) separation. 
The 2-D LC separation was performed using the Ultimate 3000 LC system 
(Thermo Scientific Dionex, Sunnyvale, CA) coupled to a Probot MALDI 
spotting device (Thermo Scientific Dionex) using parameters as described 
previously (Loei et al., 2012). Briefly, the reconstituted peptides were 
separated using a SCX 300Å NanoEase Trap column (Waters). A total of nine 
SCX fractions were collected and further separated using a RP column 
(Symmetry C18 300 µm x 150 mm NanoEase Column; Waters). Eluted RP 
fractions were then mixed with MALDI matrix (7 mg/ml α-cyano-4-
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hydroxycinnamic acid with 130 µg/ml ammonium citrate in 75% ACN) and 
spotted onto 1232-well stainless steel MALDI target plates (AB SCIEX).  
 
MS and MS/MS analyses were performed using a 4800 MALDI TOF/TOF 
Analyser (AB SCIEX). The analyses were carried out in positive ion mode 
and laser output was set to 4500 for MS acquisition and 4800 for MS/MS. 
1000 laser shots were accumulated from each sample well and precursor ions 
were selected from MS spectra ranging from 920 to 3900 Da with a minimum 
S/N ratio of 40. MS/MS analyses were performed for the seven most abundant 
precursor ions per well. Air was used for CID, with collision energy set at 1 
kV and collision gas pressure of 1x10-6 Torr. A total of 5000 shots were 
accumulated for each MS/MS spectrum.  
 
All the MS/MS spectra generated were processed using the ProteinPilot 
Software 2.0.1 (AB SCIEX) for relative quantification and protein 
identification. The processing method was set to the Paragon algorithm and all 
the spectra were searched against the International Protein Index (IPI) Human 
database (version 3.66, 86 839 total protein sequences). Search parameters 
were adjusted to indicate tryptic digestion and allow for cysteine alkylation by 
MMTS and biological modifications. The detected protein threshold score was 
set at 1.3 and the auto bias correction was applied for global normalisation. 
The spectra were also searched against a decoy database to determine the false 
discovery rate (FDR). This decoy database consisted of a randomised version 
of the IPI Human v3.66 database. The threshold for determining fold change 
was set at 1.3 based on a previous study (Tan et al., 2008). This fold change 
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threshold was derived from the standard deviation (S.D.) calculated from 
equal amounts of six-protein mixtures labelled with two iTRAQ reagents and 
analysed by LC-MS/MS. The S.D. of all the iTRAQ ratios from the identified 
peptides was 0.15 and therefore, 1.3 (1 + 2 S.D.) was determined to be the 
significant cut-off threshold. Furthermore, to ensure that the differential 
expressions observed were robust across biological variations, we applied an 
additional criterion: in order for any protein to be considered as differentially 
expressed, the difference must be observed in all the comparisons between all 
the HCT-116 and E1 biological replicates. Finally, the differentially expressed 
proteins were classified and annotated according to Gene Ontology Biological 
Processes using the AmiGO browser (Carbon et al., 2009).  
 
2.5.2. 2-D LC - ESI-qTOF analysis of whole secretome samples 
The first dimension peptide separation was performed using the Ultimate LC 
system (Dionex-LC-Packings, Sunnyvale, CA) connected to a Zorbax Bio-
SCX II column (Agilent, SantaClara, CA). The SCX solvent A was 5% ACN 
(with 0.05% FA) and solvent B was 5% ACN, 500 mM NaCl (with 0.05% 
FA). A total of 105 fractions were eluted (20μl each) over a gradient of 0 - 
20% solvent B over 90 min at a flow rate of 10 µl/min. The eluted fractions 
were subsequently combined to 18 fractions (approximately 4μg of proteins 
per fraction) and then desalted with the Sep-Pak tC18 μElution Plate (Waters) 
using a vacuum manifold (Millipore). The desalted fractions were then subject 
to a second-dimension reversed-phase (RP) chromatography on the NanoLC-
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Ultra system (Eksigent, Dublin, CA) coupled with the cHiPLC-Nanoflex 
system (Eksigent). 
 
For each SCX fraction, 2 µg of peptides were trapped on a precolumn (200 
µm x 0.5 mm) and then eluted on an analytical column (75µm x 150 mm) for 
separation. Both columns were packed with Reprosil-Pur C18-AQ 3 μm 120Å 
beads (Eksigent, Dublin, CA). The RP solvent A was 2% ACN (with 0.1% FA) 
while solvent B was 98% ACN (with 0.1% FA). The peptides were eluted 
from the analytical column in a linear gradient of 12 - 30% solvent B over 90 
min at a flow rate of 300 nL/min and then directly injected into the mass 
spectrometer for analysis.  
 
The MS analysis was performed using a 5600 TripleTOF analyzer (QqTOF; 
AB SCIEX) in the Information Dependent Acquisition mode, or DDA mode. 
Precursor ions were selected across the mass range of 350-1250 m/z using 250 
ms accumulation time per spectrum. A maximum of 20 precursors per cycle 
from each MS spectra were selected for MS/MS analyses with 100 ms 
minimum accumulation time for each precursor across a mass range of 100-
1800 m/z and dynamic exclusion for 15s. MS/MS analysis was recorded in 
high sensitivity mode with rolling collision energy on and iTRAQ reagent 
collision energy adjustment on. 
 
Protein identification and relative iTRAQ quantification were performed with 
the ProteinPilot Software 4.5 (AB SCIEX) using the Paragon algorithm for 
peptide identification and the ProGroup algorithm for grouping similar protein 
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IDs to reduce redundancy. The MS/MS spectra were searched against the 
International Protein Index (IPI) human database (version 3.87, 91 444 entries) 
with search parameters adjusted for cysteine alkylation by MMTS and 
biological modifications specified within the algorithm. The detected protein 
threshold was set at 0.05. The MS/MS spectra were also searched against a 
decoy database to estimate the false discovery rate (FDR) for peptide 
identification. The decoy database consisted of reversed protein sequences 
from the IPI human v3.87 database. 
 
We adopted a similar approach that we have previously published (Loei et al., 
2012) to distinguish between genuine secreted proteins from the intracellular 
proteins released from cell lysis. The relative abundance of all proteins in the 
CM of each cell line was compared with that of its respective whole cell lysate, 
and a cut-off ratio of > 1.5 was used to identify truly secreted proteins. In 
addition, these proteins should fulfil the cut-off requirement in both biological 
replicates. The proteins which fulfilled the above-mentioned filtering criteria 
were analysed using SecretomeP 2.0 (Bendtsen et al., 2004) to predict the 
possibility of classical and non-classical secretion. A query against the 
ExoCarta exosomal protein database (Mathivanan et al., 2012) was also 
employed to identify potential proteins released in exosomes. A 1.3 fold 
change cut-off was selected to determine differentially regulated proteins. 
Thus, proteins with HCT-116 CM / E1 CM ratios of > 1.3 would be 
considered as oversecreted, while those with ratios < 0.77 would be 
undersecreted. Gene Ontology Biological Process annotation of the 
differentially secreted proteins was performed using the AmiGO browser. 
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2.6. SWATH-MS sample preparation and analysis 
CM samples from HCT-116 and E1 cells (30 µg total protein each) were first 
reduced with 5 mM TCEP and alkylated with 10 mM MMTS. Subsequently, 
the CM proteins were digested using trypsin (Promega, Madison, WI) at a 
trypsin-to-protein ratio of 1:10 (w/w) at 37°C for 16 h. The peptides were then 
desalted using the Sep-Pak tC18 μElution Plate (WATERS) and a vacuum 
manifold (Millipore), lyophilised and finally reconstituted in 5% ACN (with 
0.1% FA) for MS analysis. Equal proportions from each of the processed 
conditioned media samples were combined to create a pooled sample, which 
were used for the generation of the reference spectral ion library as part of the 
SWATH-MS analysis. 
 
The MS analyses were performed on a TripleTOF 5600 Analyzer (QqTOF; 
AB SCIEX). The pooled sample was analysed in the Information Dependent 
Mode (Data Dependent Acquisition, DDA) as described in section 2.5.2, 
except that the iTRAQ adjustment for the rolling collision energy was 
removed. The individual conditioned media samples were analysed in the 
SWATH-MS Mode (Data Independent Acquisition, DIA), which specified for 
a quadrupole resolution of 25 Da/mass selection (Gillet et al., 2012). The 
precursor mass range was scanned across 350-1250 m/z, generating a set of 36 
overlapping windows. The collision energy for each window was set at 35 eV 
with a spread of 15 eV. Fragment ion spectra for each window were recorded 
with an accumulation time of 80 ms across the range of 100-1800 m/z each at 
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high sensitivity mode, resulting in a total cycle time of 2.98 s. Three technical 
replicates of the SWATH-MS acquisition were performed for each sample.  
 
To create a spectral library of all the detectable peptides in the samples, the 
MS/MS spectra generated from the pooled sample in DDA were searched 
using the ProteinPilot 4.5 software. Spectra identification was performed by 
searching against either the IPI (version 3.87) or the SwissProt database with 
search parameters specified for Homo sapiens sequences (20 254 entries, 
released on March 06, 2013), cysteine alkylation by MMTS and biological 
modifications specified within the algorithm. The detected protein threshold 
was set at 0.05 and a false discovery rate (FDR) analysis was also performed 
by searching against a decoy database consisting of reversed protein sequences 
from either of the IPI or SwissProt databases.  
 
2.6.1. SWATH-MS analysis for large-scale verification of iTRAQ data 
from HCT-116 and E1 secretome samples 
SWATH-MS data analysis was performed using the MultiQuant workflow for 
SRM-like quantitation. Up to three peptides with three transitions each from 
each protein were manually selected using the SWATH Acquisition MicroApp 
1.0.0.653 in the PeakView 1.2.03 software (AB SCIEX) with the following 
parameters: 25 ppm ion library tolerance, 4 min XIC extraction window, 0.01 
Da XIC width, and considering only peptides with at least 99% confidence 
and excluding those which were shared or contained modifications. Peak area 
extraction was performed using the MultiQuant 2.1 software (AB SCIEX). All 
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transition peaks were detected using a retention-time (RT) window of 45 s. A 
1-point Gaussian smooth was applied to all transition peaks, and peak areas 
were integrated using the following parameters: noise percentage at 40%, 
baseline subtraction window of 2 min and peak splitting at 2 points. Global 
normalisation was performed by adjusting the peak areas for each transition 
against the total area sums of all transitions from all proteins detectable in the 
SWATH-MS analysis. The fold change for each protein was calculated from 
the quotient of the normalised total area sum of all transition peaks of the 
protein in E1 and that in HCT-116.  
 
2.6.2. SWATH-MS analysis for label-free quantitative comparison 
between MLAC-enriched HCT-116 and E1 CM samples  
SWATH-MS quantitation was performed using the MarkerView workflow. 
Up to five peptides with three transitions per protein were automatically 
highlighted by the SWATH Acquisition MicroApp 1.0.0.653 in the PeakView 
1.2.03 software with the same parameters as described in the previous section. 
However, to ensure reliable quantitation, only proteins which had 3 or more 
peptides available for quantitation were selected for XIC peak area extraction 
and exported for analysis in the MarkerView 1.2.1 software (AB SCEIX). 
Global normalisation was performed according to the Total Area Sums of all 
detected proteins in the samples. The Student's T-test was used to perform 
two-sample comparisons between the averaged area sums of all the transitions 
derived for each protein across the three E1 and HCT-116 replicate runs, in 
order to identify proteins that were significantly differentially secreted in E1.  
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2.7. Western blot 
2.7.1. Validation of differentially expressed proteins in E1 cells 
Equal aliquots of whole cell lysates from HCT-116 and E1 were resolved by 
1-D SDS-PAGE. The gels were subsequently equilibrated in Towbin transfer 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, 20% methanol) before 
electroblotting onto PVDF membranes. The blots were then blocked overnight 
with 5% non-fat dry milk in TBS-T (20 mM Tris-HCl, 150 mM NaCl, 0.1% 
Tween-20, pH 7.5). The mouse anti-TCTP (Translationally controlled tumour 
protein; sc-133131) antibody was purchased from Santa Cruz Biotechnology, 
Inc. Mouse anti-AKAP12 (A-kinase anchor protein; H00009590-M01) and 
anti-DBN1 (Drebrin; ab12350) antibodies were purchased from Abnova and 
Abcam respectively. HRP-conjugated anti-mouse IgG (NXA931, GE-
Healthcare) was used as the secondary antibody. The immunoblotting 
conditions for each antibody are shown in Supplementary Table 1. Actin 
(A2066, Sigma-Aldrich) was used as the loading control. Visualisation was 
performed using the Enhanced Chemiluminescence system (ECL, GE-
Healthcare) or Super Signal West Dura (Pierce).  
 
2.7.2. Validation of differentially secreted proteins in the whole E1 
secretome 
The following proteins were selected for validation by western blot: GDF15 
(growth/differentiation factor 15), PAI1 (plasminogen activator inhibitor 1; 
SERPIN E1), SPARC (secreted protein, acidic, cysteine rich; osteonectin), 
MAN1A1 (mannosyl-oligosaccharide 1,2-alphamannosidase IA), and PLOD3 
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(procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3). Equal aliquots of CM 
and whole cell lysate samples from both HCT-116 and E1 cells were resolved 
by SDS-PAGE and blotted as described in the previous section. Rabbit anti-
SPARC (15274-1-AP) was purchased from Proteintech Group (Chicago, IL).  
Rabbit anti-GDF15 (ab14586) and mouse anti-PLOD3 (ab89263) antibodies 
were purchased from Abcam (Cambridge, UK). Mouse anti-PAI1 (sc-5297) 
and rabbit anti-MAN1A1 (M3694) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and Sigma-Aldrich respectively. The 
immunoblotting conditions for the antibodies used are detailed in 
Supplementary Table 1. The secondary antibodies used were HRP-conjugated 
anti-mouse IgG (NXA931, GE-Healthcare) and HRP-conjugated anti-rabbit 
IgG (1858415, Pierce Biotechnology). Visualisation was performed using 
either the Enhanced Chemiluminescence (ECL) substrate (GE-Healthcare) or 
Super Signal West Dura (Pierce Biotechnology). 
 
2.7.3. Validation of differentially secreted proteins in E1 from the 
MLAC-enriched glyco-secretomes 
Equal aliquots of CM and whole cell lysate samples from HCT-116 and E1 
cells were resolved by SDS-PAGE and blotted as described in the previous 
section. Rabbit anti-COL6A2 (14853-1-AP) was purchased from Proteintech 
group (Chicago), while mouse anti-LAMB1 (sc-17810) was purchased from 
Santa Cruz Biotechnology (Santa Cruz). The immunoblotting conditions for 
the antibodies used are detailed in Supplementary Table 1. The secondary 
antibodies used were HRP-conjugated anti-mouse IgG (NXA931, GE-
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Healthcare) and HRP-conjugated anti-rabbit IgG (1858415, Pierce 
Biotechnology). Visualisation was performed using Super Signal West Dura 
(Pierce Biotechnology) together with the ChemiDoc MP System (Bio-Rad, 
Hercules, CA) and the ImageLab v4.1 software (Bio-Rad). 
 
2.8. Immunohistochemical analysis in clinical patient tissues  
Seven colorectal cancer patient adenocarcinoma tissue sections with matched 
lymph node and liver metastases were obtained from the Department of 
Pathology, Singapore General Hospital, with the appropriate ethics approval. 
The clinical information of the seven patient tissue samples is detailed in 
Supplementary Table 2. The tissue slides were stained using the REAL 
EnVision Detection Systems Peroxidase/DAB (Dako, Denmark) according to 
the manufacturer’s recommendations with some modifications. Antigen 
retrieval was performed using Tris-EDTA (pH 9) at 100oC for 5 min. 
Endogenous peroxidase activity was inhibited by treating the slides with 
REAL Peroxidase-Blocking solution (Dako) for 10 min. The slides were then 
incubated with the anti-DBN1 antibody (ab12350, Abcam) diluted in REAL 
Antibody diluent (Dako) at 1:200 for 2 hrs. Secondary antibody (Dako REAL 
EnVision/HRP, Rabbit/Mouse) incubation was performed for 30 min, 
followed by the DAB chromogen buffer (Dako REAL DAB+ Chromogen) for 
15 min. The slides were then counterstained with haematoxylin. Serial staining 
of the colon adenocarcinoma tissue sections against neurofilaments (NF) was 
performed on the Leica Bond-III automated IHC stainer (Leica Microsystems, 
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Germany) using the Bond Polymer Refine Detection method with an anti-
neurofilament antibody (M0762, Dako).  
 
Scoring was performed by Dr. KH Lim (Department of Pathology, Singapore 
General Hospital). The diagnoses for the patient samples were histologically 
confirmed in the stained tissue sections and the scorer was blind to the 
clinicopathological information. The immunostaining was assessed as follows: 
staining intensity (I) was graded according to negative (0), mild staining (1), 
moderate staining (2) and strong staining (3). Percentage of cells stained (P) 
were classified as: <10% (0), 10–29% (1), 30–49% (2), 50–79% (3) and >80% 
(4). The overall staining index for each slide was therefore evaluated as I x P. 
Statistical analyses were performed using the OriginPro 8.5 software 
(OriginLab, Northampton, MA). The paired Wilcoxon signed rank test was 
used to compare the staining indices of the primary tumour tissues to their 
matched lymph node and liver metastases.   
 
2.9. ELISA analysis on clinical patient serum samples 
A total of 19 serum samples from colorectal cancer patients, as well as 47 
serum samples from healthy individuals free of any cancer, were obtained 
from the NUH-NUS (National University Hospital - National University of 
Singapore) Tissue Repository. An additional 26 serum samples from 
colorectal cancer patients were further obtained from the SingHealth Tissue 
Repository. The clinical information of the 45 colorectal cancer patient 
samples that could be accessed is detailed in Supplementary Table 3. This 
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study was conducted with approval from the relevant Institutional Review 
Boards. 
 
The concentrations of LAMB1 in the serum samples were measured using 
commercial ELISA kits from USCN Life Sciences Inc. (SEA184Hu), 
according to the manufacturer’s protocol. All plate washing steps were carried 
out using the ELx50 Microplate strip washer (BioTek, Winooski, VT). The 
absorbance readings were measured using the Tecan Infinite M200 
spectrophotometer (Tecan, Männedorf, Switzerland). The ELISA data was 
analyzed with the statistical software OriginPro 8.6 (OriginLabs) and 








































3.1.1. Identification of differentially expressed intracellular proteins 
in E1 cells as compared to HCT-116 
In order to identify differentially expressed proteins in E1 as compared to 
HCT-116 cells, we compared the intracellular proteomes of HCT-116 and E1 
cells using the iTRAQ technology. We identified a total of 547 proteins in 
both cell lines with at least 95% confidence, after considering only those 
which were identified with two peptides and above, as well as discarding any 
hits that were false positives or without iTRAQ ratios.  
 
Due to problems in protein quantitation of the HCT-116 and E1 replicates that 
were labelled with the iTRAQ Tag113 and Tag121 respectively, these were 
excluded from downstream analyses. Consequently, only iTRAQ ratios from 
three replicates each of HCT-116 and E1 were considered for determining 
differences in expression levels of the proteins. Two criteria were applied to 
determine the list of differentially expressed proteins in E1: (i) only proteins 
with iTRAQ ratios of above 1.3 or below 0.77 would be considered as 
differentially expressed; (ii) the protein must also be differentially expressed 
in all three E1 biological replicates across all nine comparisons. With these 
two criteria, a total of 31 proteins were determined to be differentially 
expressed in E1 (Table 3). 20 proteins were found to be overexpressed in E1, 
while the list of underexpressed proteins consisted of 11 members. Gene 
Ontology Biological Processes classification of these 31 proteins indicated 
that they are involved in metastasis-related processes such as gene expression, 




3.1.2. Western blot validation of iTRAQ data 
In order to confirm the altered expression of differentially expressed proteins 
in E1, a selection of three proteins was chosen for validation. The differential 
expressions of two overexpressed proteins, DBN1 and TCTP, and one 
underexpressed protein, AKAP12, were confirmed with western blot using 
commercially available antibodies (see Figure 8A). Parallel immunoblotting of 
Actin was used as loading control. The visualised antibody signals were 
quantified by scanning the respective blots on a densitometer (summarised in 
Figure 8B). The expression of TCTP was significantly increased in all three 
E1 replicates (p = 0.0125). Similarly, DBN1 was also significantly 
overexpressed in E1 (p = 0.0094). Conversely, the expression levels of 








Table 3. Differentially expressed proteins in E1 cell line identified from iTRAQ analysis 















Figure 8. Western blot validation of selected differentially expressed proteins in E1  
(A) Differential expression of TCTP, DBN1 and AKAP12 suggested from the iTRAQ 
data, validated using western blot in three biological replicates each from HCT-116 and E1 
cells. The immunoreactive bands are shown here together with their respective actin 
loading controls. (B) Quantification of the immunoreactive bands detected from TCTP, 
DBN1 and AKAP12 using a densitometer. The averaged readings from the three 
biological replicates normalised against actin are shown with the error bar denoting 
standard deviation. Statistical analyses were performed using the Student's T-test. Figure 
































3.1.3. Immunohistochemistry analyses of DBN1 
The relevance of DBN1 overexpression in clinical colorectal cancer metastasis 
was assessed using immunohistochemical (IHC) analyses of colorectal cancer 
patient tissues (Figure 9). DBN1 expression was observed to be negative in 
most of the primary tumour sections (Figure 9A), with the exception of one 
case which was stained weakly positive (Figure 9B). Since DBN1 is a 
neuronal protein, we compared the localisation of DBN1 in the primary 
tumour sections against serial neurofilaments (NF) immunostain, and observed 
that DBN1 localisation indeed corresponded with that of NF (Figure 10). 
Therefore, we used the presence of DBN1 expression in the neuronal cells in 
the primary tumour sections as an internal positive control. In contrast, in the 
matched lymph node and liver metastasis sections, DBN1 stained positive for 
all seven cases (Figures 9C-D). Localisation of DBN1 was observed to be 
mainly cytoplasmic in both lymph node and liver metastases, with indications 
of juxtamembrane enrichment observable at higher magnifications (see 
Figures 9E-F). The staining indices for the sections are summarised in Figure 
9G. Paired Wilcoxon signed-rank tests confirmed that DBN1 was indeed 
significantly overexpressed in the matched lymph node (p = 0.0078, n = 7) and 







Figure 9. Immunohistochemical analyses of DBN1 expression in clinical colorectal 
cancer patient samples  
DBN1 immunostaining in primary tumour tissue sections (A-B), with matched lymph 
node (C) and liver metastases (D) sections (20x magnification). (E-F) Higher 
magnification (40x) reveal indications of DBN1 juxtamembrane enrichment (indicated 
by arrows). Scale bars indicate 50.18 µm. (G) Distribution of the number of patient 
tissue sections in the primary adenocarcinoma sections with matched lymph node and 
liver metastases, plotted against staining indices scored for DBN1 expression. The 
colours of the bars denote the staining indices scored with darker shades of blue 
indicating higher staining index, while the number within each bar indicate its respective 
staining index. Statistical analyses were performed using the paired Wilcoxon signed-
rank tests. Figure reproduced from Lin et al., 2014, with permission from Proteomics, 














































Figure 10. Serial staining of colon adenocarcinoma tissue sections against DBN1 and 
neurofilament (NF) 
Comparisons between serial staining of colon adenocarcinoma tissue sections against NF 
(A) and DBN1 (B) showed that localisation of the DBN1 signal corresponded with that of 
NF. Images at 4x magnification. The dotted box indicates the area that is represented in the 
magnified inset image (at 20x magnification). Scale bars indicate 50.18 μm. Figure 














3.2. Part Two. Comparative analysis of the HCT-116 and E1 













3.2.1. The HFC system is a viable alternative for CM preparation 
When Wu and colleagues (2009) proposed the use of the HFC system as an 
alternative for CM preparation, they also studied the levels of intracellular 
contaminants in the HFC system. By analysing the levels of housekeeping 
intracellular proteins (such as G3PDH, Hsp60, tubulin and actin) in the CM 
prepared from the HFC system as opposed to dish culture, they discovered that 
the cell lysis rate in the HFC system was 0.001-0.022%, as compared to the 
0.32-1.84% in dish culture (Wu et al., 2009).  
  
To further investigate the culture conditions in the HFC system as compared to 
traditional culture methods, we performed an iTRAQ-based comparison 
between the whole cell lysate profiles of HCT-116 and E1 cells cultured in 
flasks and the HFC system. A total of 990 proteins were identified within 1% 
local FDR and matched by at least two peptides. Using a 1.3 fold-change cut-
off threshold, 57 and 70 proteins were observed to be overexpressed in HCT-
116 and E1 cells cultured in the HFC system as compared to flask culture, 
with an overlap of 26 proteins in both cell lines. Similarly, 144 and 89 proteins 
were underexpressed in HCT-116 and E1 cells cultured in the HFC system, of 
which 76 proteins were common to both cell lines (Figure 11A, see 
Supplementary Table 4-5 for list of differentially expressed proteins). Gene 
Ontology Biological Process annotation enrichment analysis indicated that 
metabolic processes, gene expression and biosynthetic processes were 
enriched in the proteins which were overexpressed in both cell lines when 
cultured in the HFC system (Figure 11B). Conversely, terms related to stress 
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response and regulation of cell death were enriched in underexpressed proteins 
in both cell lines which were cultured in the HFC system (Figure 11C).  
 
Our data extends the observations reported by Wu and colleagues (2009) that 
the HFC system provides better growth conditions for CM collection. More 
interestingly, we found that even though in serum-deprived conditions, the 
cells cultured in the HFC system had higher levels of proteins associated with 
proliferation and growth, while lower levels of those involved in stress 
response and cell death. The implications of this are particularly important, 
since serum-deprivation has often been criticised of inducing reductions in cell 
proliferation (Cooper, 2003; Shin et al., 2008), increasing cell death (Hasan et 
al., 1999), and alterations in protein synthesis and secretion patterns (Zander 
and Bemark, 2008). Therefore, the large surface area for growth and the 
dynamic removal of waste provided by the HFC system seems to mitigate to 
some extent the detrimental effects of serum-deprivation. In addition, coupled 
with the capability for concentrating secreted proteins in a small culture 
volume, the HFC system appears to be a highly attractive and viable 













Figure 11. iTRAQ analysis of proteins differentially expressed in HCT-116 and E1 
cells cultured in the HFC system as compared to culture flasks 
(A) Number of proteins that were differentially expressed in HCT-116 and E1 cells 
cultured in the HFC system as compared to culture flasks (B) Gene Ontology Biological 













































































3.2.2. iTRAQ analysis of HCT-116 and E1 secretomes 
To identify differentially secreted proteins between HCT-116 and E1 cells 
which could be potential biomarkers for colorectal cancer metastasis, we 
performed an iTRAQ-based comparison between HCT-116 and E1 CM 
samples prepared using the HFC system. A total of 1201 proteins were 
identified using a 1% local FDR and with at least two peptides. To distinguish 
between genuine secreted proteins from intracellular contamination, we 
utilised an approach that we have previously published whereby the relative 
abundance of the proteins in the CM of each cell line were compared with that 
of its respective whole cell lysate (Loei et al., 2012). This was based on the 
premise that secreted proteins would most likely be in higher abundance in the 
CM as compared to the cell lysate. Therefore, by applying a CM / Lysate cut-
off ratio of more than 1.5, we would be able to differentiate between genuine 
secreted proteins from intracellular proteins released from cell lysis. Using this 
approach, we identified a total of 127 putative secreted proteins, of which 110 
were common to both cell lines, nine were secreted only in HCT-116 cells, 
and eight were secreted only in E1 cells (Figure 12A). 
 
When analysed using the SecretomeP secretion prediction server, 91 (72%) of 
the 127 putative secreted proteins were predicted to contain a N-terminal 
signal peptide, while 17 (13%) were predicted to be secreted using non-
classical secretory mechanisms (Figure 12B). The remaining 19 unconfirmed 
proteins were further queried against the ExoCarta exosomal protein database 
and among these, 12 were reportedly secreted through exosomal release. In 
69 
 




Subsequently, to identify differentially secreted proteins in colorectal cancer 
metastasis, we compared the levels of the 127 secreted proteins in HCT-116 
and E1 cells. Using a fold-change cut-off of 1.3, a total of 38 proteins were 
observed to be differentially secreted in the E1 CM (Table 4), of which 15 
proteins were oversecreted in E1 cells, while 23 were undersecreted in E1 






Proteins with CM/Lysate Ratio >1.5









Figure 12. Overview of HCT-116 and E1 secretomes 
(A) Number of proteins with CM/Lysate ratios of more than 1.5, indicating possible 
secretion. A total of 127 putative secreted proteins were identified, with 110 proteins 
common to both cell lines, nine secreted in HCT-116 only and eight secreted in E1 only. 
(B) Secretion prediction analysis of the 127 putative secreted proteins using the 
SecretomeP software and ExoCarta database. 91 proteins contained a signal peptide 
sequence, which would target the protein for secretion through the classical secretory 
pathway, and 29 proteins were predicted to be secreted non-classically. The remaining 
seven could not be confirmed.  
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Table 4. Continued 
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3.2.3. Large-scale verification of iTRAQ data using SWATH-MS for 
SRM-like targeted quantitation 
To increase the confidence in the list of differentially secreted proteins that 
were identified by the iTRAQ analysis, we decided to perform a MS-based 
large-scale verification of the iTRAQ data by using SWATH-MS acquisition 
to perform SRM-like targeted quantitation. A total of three technical replicates 
from each of the two HCT-116 and E1 CM biological replicates were analysed 
using SWATH-MS acquisition, while the spectral library was generated using 
DDA on a pooled sample from all the CM samples. For targeted quantitative 
analysis of the above-mentioned 38 differentially secreted proteins in E1, 
peptides and transitions suitable for quantitation were manually selected using 
the SWATH Acquisition MicroApp in the PeakView software. Subsequently, 
extraction of the peak areas from the extracted ion chromatograms (XICs) of 
the selected peptides and transitions was performed using the MultiQuant 
software. For each protein, the peak areas from its respective peptides and 
transitions extracted from the three technical replicates were summed (denoted 
as "total area sum"), and this was used as a representation of the relative 
abundance of the protein in the sample. Finally, the fold change ratio of the 
protein was then calculated by the quotient of the total area sum of the protein 
in the E1 CM sample divided by that in the HCT-116 CM sample (Table 5). 
Using this approach for targeted quantitative analysis, we observed that among 
the 38 differentially secreted proteins in E1, 25 proteins (66%) were 





Table 5. Differentially secreted proteins which showed similar trends in both iTRAQ and SWATH-MS analysis 
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Eight proteins (LIF, GGH, TRIP10, PTPRk, PROCR, FURIN, DDX21 and 
ADM) were not detected in the SWATH-MS analysis, while the differential 
secretion of five (CANT1, PAM, VCAN, QSOX1 and CDCP1) reported by 
the SWATH-MS analysis differed from that in the iTRAQ analysis. Therefore, 
downstream analyses were only performed on the 25 differentially secreted 
proteins which were corroborated by both iTRAQ and SWATH-MS 
quantitative analyses. Gene Ontology Biological Process annotation of these 
25 differentially secreted proteins in E1 indicated that they could be involved 
in processes such as signal transduction, adhesion and migration, as well as 
protein processing and post-translational modifications (Figure 13).  
 
 
Figure 13. Gene Ontology Biological Process annotation of the 25 differentially 
secreted proteins in the E1 secretome 
Gene Ontology Biological Process annotation was performed on the 25 secreted proteins 
which showed similar differential trends in both iTRAQ and SWATH-MS analyses. 



























3.2.4. Western blot validation of selected candidate proteins 
differentially secreted in E1 cells 
To verify the differential secretion of the proteins in E1 as suggested by the 
iTRAQ data, we selected five proteins for western blot validation. These five 
proteins were oversecreted in E1 cells and included well-known dysregulated 
secreted proteins in colorectal cancer such as GDF15, PAI1, SPARC, as well 
as potentially novel players such as MAN1A1 and PLOD3.   
 
The levels of the abovementioned five proteins were assessed in both the CM 
and lysates of HCT-116 and E1 cells using commercially available antibodies. 
The oversecretion of the five selected proteins in the HCT-116 and E1 CM 
were consistent with both the iTRAQ and SWATH-MS data (Figure 14). The 
molecular weights (MW) of the immunoreactive bands from MAN1A1 in the 
CM samples were lower than its theoretical MW and presumably represented 
a truncated form of the protein with its signal peptide cleaved. The 
immunoreactive bands from MAN1A1 in the whole cell lysates samples 
corresponded to its theoretical MW, while the levels of the other 4 proteins 
were too low to be detected in the whole cell lysates of HCT-116 and E1 
under the immunoblotting conditions. In addition, we also probed for the 
presence of Lamin B, a component of the nuclear lamina, as a control to assess 
the level of intracellular contamination in the CM samples. Typical 
housekeeping proteins, such as GAPDH and actin, were not used because they 
have been detected to be present in exosomes previously (Mathivanan et al., 
2012). We were unable to detect any Lamin B in HCT-116 and E1 CM 
samples from both biological replicates, although strong immunoreactive 
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bands were detected from the whole cell lysate samples. Therefore, this 
indicated that our CM samples should have minimal intracellular 
contamination.    
 
 
Figure 14. SWATH-MS and western blot analysis of selected differentially secreted 
proteins in E1 
Differential secretion of (A) GDF15, (B) SPARC, (C) SERPINE1, (D) PLOD3 and (E) 
MAN1A1 suggested by the iTRAQ data, validated using both SWATH-MS and western 
blot. SWATH-MS analyses were performed on CM samples only, and representative 
extracted ion chromatograms (XICs) from one peptide of each protein are shown here. 
Western blot analyses were performed on both CM and whole cell lysate samples. 
Samples from HCT-116 [H] and E1 [E] from both biological replicates [R1 and R2] were 
analysed. (F) LaminB, a component of the nuclear lamina, was used as a control to 
confirm the absence of intracellular contamination in the CM samples. 
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3.3. Part Three. SWATH-MS quantitative analysis of HCT-116 and 












In the spectral library generated using DDA from the pooled sample, a total of 
568 proteins were identified using a 1% local FDR and with at least two 
peptides. Using the criteria of selecting only those proteins which had 3 or 
more peptides suitable for quantitation, 421 proteins were selected for further 
quantitative analyses. Using SecretomeP in the same manner as described 
earlier, 287 of the 421 proteins (68%) were predicted to contain an N-terminal 
signal peptide, while 53 (13%) were predicted to be secreted using non-
classical secretion pathways (Figure 15). The remaining 81 unconfirmed 
proteins were then searched against the ExoCarta database, and 66 of these 
have been previously discovered in exosomes. In total, 406 of the 421 proteins 
(96%) could be confirmed to be secreted through various mechanisms. In 
addition, when queried against the UniProt database, 294 of the 421 proteins 




Figure 15. Overview of the HCT-116 and E1 glycosecretomes 
(A) Secretion prediction on the 421 proteins selected for quantitative analyses using the 
SecretomeP software and ExoCarta database. A total of 287 of these proteins were 
predicted to be secreted by the classical secretory pathway, while 119 proteins were 
predicted to be secreted non-classically. The remaining 15 proteins could not be 
confirmed. (B) A total of 294 proteins were found to contain at least a single 
glycosylation site when queried against the UniProt database, while there was no 
evidence of any known or potential glycosylations for the remaining 127 proteins.  
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A total of three technical replicates from each HCT-116 and E1 MLAC-
enriched CM sample were analysed using the SWATH-MS acquisition. For 
quantitative analysis of the above-mentioned 421 proteins, peptides and 
transitions suitable for quantitation were automatically selected using the 
SWATH Acquisition MicroApp in the PeakView software, and their 
respective XIC peak areas were extracted and exported for analysis in the 
MarkerView software. To control for uneven sample loss across the different 
samples during the sample preparation process, we performed a global 
normalisation based on the total sum of all the peak areas extracted from all 
the peptides and transitions across the three technical replicates of each CM 
sample. The basis for this was that given the similar genetic backgrounds of 
the HCT-116 and E1 cell lines, majority of the proteins should have relatively 
similar abundances across the two cell lines.  
 
After the normalisation process, we used the Student's T-test to perform a 
statistical comparison of the average extracted peak area for each protein in 
the E1 MLAC-enriched CM, with respect to that in HCT-116. An overview of 
the analysis is shown in Figure 16, where the logarithm of the fold change for 
each of the 421 selected proteins, in E1 as compared to HCT-116, is plotted 
with its respective p-value from the Student's T-test analysis. To select for 
statistically significant differentially secreted proteins in the E1 MLAC-
enriched CM, we only considered secreted glycoproteins which showed more 
than the 1.3 fold-change difference with p-values of less than 0.05. Using 
these criteria, a total of 149 glycoproteins were observed to be differentially 




Figure 16. SWATH-MS quantitative analysis of HCT-116 and E1 MLAC-enriched CM 
(A) Quantitative analysis of the 421 proteins identified in both HCT-116 and E1 MLAC-enriched CM samples, depicted in the form of a volcano plot. The logarithm of 
the fold change ratio for each protein in the E1 CM as compared to HCT-116 was plotted with respect to its respective p-value. The secreted glycoproteins which show 
statistically significant undersecretion in the E1 CM are highlighted in green, with their relative abundances in each sample plotted in (B), and those with significant 
oversecretion in the E1 CM are highlighted in red, with their relative abundances plotted in (C). 
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Table 6. Continued 
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Of the 149 differentially secreted glycoproteins identified, 74 glycoproteins 
were oversecreted in the E1 MLAC-enriched CM as compared to that of HCT-
116, while 75 were undersecreted. According to the Gene Ontology Biological 
Process annotation, a large portion of these proteins could be mapped to 
processes important in metastasis, such as adhesion and ECM organisation, 





Figure 17. Gene Ontology Biological Process annotation of the 149 differentially 
secreted proteins in the E1 glycosecretome 
Gene Ontology Biological Process annotation was performed on the 149 secreted 
glycoproteins which showed differential secretion levels in the SWATH-MS analysis of 
































3.3.1. Western blot validation of selected candidate glycoproteins 
differentially secreted in E1 cells 
All of the five secreted proteins that were selected for western blot validation 
in the previous chapter (GDF15, SPARC, SERPINE1, PLOD3 and MAN1A1; 
see section 3.2.4) were also identified to be oversecreted in the E1 MLAC-
enriched glycosecretome. Therefore, to further verify the differential secretion 
of the glycoproteins in the E1 CM as suggested by the SWATH-MS 
quantitative analysis, we selected two other ECM proteins, collagen type VI, 
α-2 (COL6A2) and laminin, β-1 (LAMB1) for validation using western blot.  
 
The levels of COL6A2 and LAMB1 were assessed in both CM and lysate 
samples from HCT-116 and E1 cells using commercially available antibodies. 
The oversecretions of COL6A2 and LAMB1 in the E1 CM were shown to be 
as consistent as indicated by the SWATH-MS data (Figure 18A-B). Similar to 
the other differentially secreted proteins assessed by western blot in the earlier 
section, levels of COL6A2 and LAMB1 were too low to be detected in the 
whole cell lysates from both HCT-116 and E1 cells under the immunoblotting 
conditions. In addition, the absence of Lamin B indicated that the CM samples 






Figure 18. Representative SWATH-MS spectra and western blot analysis of COL6A2 
and LAMB1 levels in HCT-116 and E1 CM samples 
Differential secretion of (A) COL6A2 and (B) LAMB1, suggested by the iTRAQ data, 
were validated using western blot. Representative extracted ion chromatograms (XICs) 
from two peptides of each protein are shown here. Western blot analyses were performed 
on both CM and whole cell lysate samples. Samples from HCT-116 [H] and E1 [E] 
conditioned media and whole cell lysate samples were analysed. (C) Lamin B (LMNB1), a 
component of the nuclear lamina, was again used here as a control to confirm the absence 
















































3.3.2. LAMB1 levels were significantly higher in serum of colorectal 
cancer patients as compared to healthy controls 
The levels of LAMB1 in the 45 colorectal cancer patient serum samples were 
measured to be 282.0 ± 405.1 ng/ml (mean ± SD), which were significantly 
higher than in the 47 healthy control samples, 28.6 ± 17.8 ng/ml (p = 1.39 x 
10-9, Mann-Whitney test; Figure 19A). The 45 colorectal cancer patients were 
also further classified according to the modified Dukes' classification 
(Supplementary Table 3), but there appeared to be no significant difference 
between LAMB1 serum levels in patients with different Dukes' staging (p = 
0.27, Kruskal-Wallis ANOVA, Figure 19C). In addition, we performed a 
receiver operating characteristic (ROC) analysis to assess the diagnostic 
performance of LAMB1 for colorectal cancer. In discriminating between 
colorectal cancer patients and healthy controls, the area under the ROC curve 
(AUC) was 0.86 (95% confidence interval, 0.786 - 0.934; Figure 20A). When 
a cut-off value of 58.0 ng/ml was applied, LAMB1 could distinguish between 
colorectal cancer patients from healthy controls with a sensitivity of 64% and 








Figure 19. LAMB1 and CEA serum levels in colorectal cancer patients and healthy 
controls 
The levels of (A) LAMB1 and (B) CEA were measured in serum samples from 45 
colorectal cancer patients and 47 healthy individuals using ELISA. Serum LAMB1 and 
CEA levels were both significantly higher in colorectal cancer patients as compared to 
controls. Statistical analyses were performed using the Mann-Whitney Test. (C-D) The 
colorectal cancer patients were further categorised according to the modified Dukes' 
classification. However, there was no significant difference in both serum LAMB1 and 
CEA levels between patients of different Dukes' staging. Data are represented as the 
upper and lower quartiles and interquartile range (box), the median (horizontal line), the 

















































To assess the performance of LAMB1 against the current gold standard in the 
clinic, we also measured the levels of CEA in the same serum samples. 
Similarly, CEA levels in the serum of colorectal cancer patients were 
significantly higher than in the healthy controls (27.2 ± 51.5 ng/ml vs. 2.5 ± 
2.6 ng/ml, p = 3.18 x 10-5; Figure 19B). In addition, there was no significant 
difference between CEA serum levels in patients with different Dukes' staging 
as well (p = 0.30, Figure 19D). The AUC for CEA in distinguishing between 
colorectal cancer patients from healthy controls was 0.74 (95% confidence 
interval, 0.64 - 0.85; Figure 20B), and with the typical cut-off value of 5.0 
ng/ml used in the clinic (Jeon et al., 2013), the sensitivity and specificity were 
53% and 89% respectively.  
 
Our results showed that LAMB1 performed better than CEA in discriminating 
colorectal cancer patients from healthy controls, with higher sensitivity and 
specificity. More importantly, when LAMB1 was used in combination with 
CEA, the AUC was further improved to 0.91 (95% confidence interval, 0.85 - 
0.97; Figure 20C), and the sensitivity was increased to 80%, while the 













Figure 20. ROC analysis of the diagnostic performance of LAMB1 in comparison to 
and combination with CEA. 
ROC curves of (A) LAMB1, (B) CEA, and (C) LAMB1 in combination with CEA in 
discriminating colorectal cancer patients from healthy controls. (D) Diagnostic 
performance of LAMB1 (at cut-off levels of 58.0 ng/ml), as compared to that of CEA (at 
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4.1. Part One. iTRAQ analysis of HCT-116 and E1 cells suggests 








In order to further the understanding of the molecular mechanisms that drive 
colorectal cancer metastasis, we sought to identify potentially novel 
metastasis-related proteins by comparing the intracellular proteomes of the 
isogenic pair of colon cancer cell lines, HCT-116 and E1. The key advantage 
of using the HCT-116 and E1 cell lines as a model for studying colorectal 
cancer liver metastasis lies in the fact that E1 was generated from HCT-116. 
Karyotype analyses of the parental HCT-116 cells and metastatic-derivative 
E1 cells confirmed that their genetic backgrounds are largely similar (Tay et 
al., 2010). Therefore, we postulated that any differences between E1 and 
HCT-116 could potentially be involved in conferring the aggressive metastatic 
phenotype on E1. Using an iTRAQ-based comparative analysis of the HCT-
116 and E1 intracellular proteomes, a total of 31 proteins were determined to 
be differentially expressed in E1. Furthermore, these proteins appeared to be 
involved in metastasis-related processes such as gene expression, signal 
transduction, cell proliferation and cytoskeletal organisation (Table 3).  
 
4.1.1. Differential expression of proteins involved in gene expression, 
transcription and translation 
Several proteins involved in gene expression, such as protein LYRIC (MTDH) 
and p180/ribosome receptor (RRBP1), were observed to be overexpressed in 
E1 cells. MTDH is involved in diverse aspects of tumour progression and its 
overexpression has been observed to correlate to poor clinical outcomes in 
many different tumours (Hu et al., 2009). Overexpression of RRBP1 has been 
previously observed in breast (Telikicherla et al., 2012) and lung (Tsai et al., 
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2013) cancer patient tissues, and was suggested to be involved in promoting 
tumour cell survival by protecting against ER stress (Tsai et al., 2013). 
 
4.1.2. Perturbation of proteins involved in signalling and regulation 
of apoptosis 
During tumourigenesis and metastatic transformation, the regulation of 
apoptosis is inevitably perturbed in order to enhance survival. Therefore, we 
were hardly surprised to observe the overexpression of proteins such as 
annexin A5 (ANXA5), Lamin-A/C (LMNA) and the translationally controlled 
tumour protein (TCTP) in E1 cells. ANXA5 has been reported to be correlated 
to colorectal cancer staging and increased expression of ANXA5 has been 
shown to be prognostic for liver metastasis (Xue et al., 2009). Expression of 
LMNA has been similarly found to be related to mortality in colorectal cancer 
and is thought to influence metastasis through up-regulation of T-plastin 
which consequentially down-regulates E-cadherin (Willis et al., 2008). 
 
Overexpression of TCTP is a common observation in diverse types of tumours, 
since TCTP is a highly conserved, ubiquitous and multi-functional survival 
factor. It has been shown to regulate cell growth in diverse cell types across 
different organisms and involved in various processes such as cytoskeletal 
organisation and protein synthesis (Telerman and Amson, 2009). TCTP can 
also influence reprogramming of somatic cell nuclei to express proteins 
characteristic of embryo cells by transcriptional activation of oct4 and nanog 
genes, which are well-known in establishing pluripotency (Koziol et al., 2007). 
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Furthermore, TCTP has also been suggested to be anti-apoptotic by interfering 
with BAX-induced apoptosis through its interactions with BCL-XL and 
MCL1 (Susini et al., 2008). More interestingly, TCTP has been identified to 
be most strongly down-regulated in tumour reversion models generated from 
human leukaemia and breast cancer cells (Tuynder et al., 2004).  
 
Using western blot, we further validated that TCTP levels were indeed 
significantly increased in all three E1 replicates (p = 0.0125; Figure 8). Our 
findings corroborated those reported by Chung and colleagues (2000), who 
found that expression of TCTP are up-regulated at both mRNA and protein 
levels in colorectal cancer tissues. A recent study further revealed that 
knockdown of TCTP in colon cancer cell lines resulted in reduction of 
proliferation, migration and invasion (Ma et al., 2010). 
 
Another regulator of apoptosis identified in this study was the A-kinase anchor 
protein 12 (AKAP12; Gravin, AKAP250). AKAP12 was originally discovered 
as a minor autoantigen that correlated to poor prognosis in myasthenia gravis 
patients (Gordon et al., 1992; Sasaki et al., 2001). It is currently understood to 
function as a scaffolding protein and coordinates signalling and cytoskeletal 
reorganisation through binding of key players such as protein kinases A and C 
(PKA and PKC) (Gelman, 2010). There are many lines of evidence to indicate 
that AKAP12 is likely to be a tumour suppressor. The AKAP12 gene has been 
mapped to chromosome 6q24-25.2, which has been shown to be a deletion 
hotspot in prostate, breast and ovarian cancers (Gelman, 2002). Furthermore, 
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expression of AKAP12 has been reported to be down-regulated in a large 
variety of cancers (reviewed in Gelman, 2010).  
 
Our iTRAQ data indicated a similar reduction in the levels of AKAP12 in E1 
cells, and this was also confirmed to be significant using western blot (p = 
0.0095; Figure 8). This suggests that AKAP12 could likely function likewise 
as a tumour suppressor in colorectal cancer metastasis. Indeed, the AKAP12 
promoter region has been found to be hypermethylated in several types of 
colorectal cancer cell lines and primary colorectal cancer tissue samples, and 
the extent of methylation could be correlated with advanced Dukes' stages 
(Liu et al., 2010a; Mori et al., 2006). Moreover, when AKAP12 was re-
expressed in the colorectal cancer lymph node metastatic-derived LoVo cells, 
apoptosis was induced and reductions in migration, invasion and anchorage-
independent growth were observed (Liu et al., 2011). Although the authors 
only showed that LoVo-cells overexpressing AKAP12 were less effective in 
metastasis to the lung in nude mice, our data indicates that AKAP12 might 
play a similar tumour suppressive role in colorectal cancer liver metastasis. As 
such, AKAP12 may be a promising target for novel therapeutic interventions 
against colorectal cancer metastasis.  
 
4.1.3. Dysregulation of proteins involved in reorganisation of the 
cytoskeleton 
One of the most important steps in cancer metastasis is the acquisition of 
enhanced motility in tumour cells through dynamic remodelling of the 
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cytoskeleton. Therefore, proteins that are involved in cytoskeletal 
reorganisation are inevitably targets of dysregulation during tumourigenesis 
and metastasis. Three such proteins were identified to be overexpressed in E1 
cells: actinin-4 (ACTN4), stathmin-1 (STMN1) and drebrin (DBN1). ACTN4 
has been previously reported to be involved in colorectal cancer lymph node 
metastasis (Honda et al., 2005), while we (Tan et al., 2012) and others (Abal 
et al., 2007; Zheng et al., 2010) have shown that overexpression of STMN1 in 
colorectal cancer resulted in increased metastatic capabilities in tumour cells, 
and can also be correlated to poorer patient prognosis.  
 
Drebrin (developmentally regulated brain protein; DBN1) is an actin-binding 
protein that was originally discovered from chicken embryo brains (Shirao et 
al., 1988). Alternative splicing results in four isoforms of DBN1: E1 and E2 
(embryonic), A (adult) and s-A (truncated form of A), although only the E2 
and s-A isoforms have been identified in mammals (Jin et al., 2002; Kojima et 
al., 1993; reviewed in Dun and Chilton, 2010). DBN1 was initially believed to 
be a neuronal-specific protein which regulates migration and differentiation of 
axons and dendrites during brain development. However, there have been 
several studies reporting the presence of DBN1 in various non-neuronal 
tissues, such as stomach, kidney, bladder and eccrine sweat glands (Keon et al., 
2000; Peitsch et al., 2005; Peitsch et al., 2003). There is some evidence to 
indicate that DBN1 may be similarly involved in regulating actin plasticity in 
non-neuronal cells. For example, it has been found to accumulate at the 
extended apical membrane of parietal cells and also able to induce a 




DBN1 has been reported to be up-regulated in epithelial skin tumours (Peitsch 
et al., 2005), recurrent non-small cell lung cancer (Mitra et al., 2011), and in 
lymphoblastic leukaemia (Vaskova et al., 2011). Our results from both iTRAQ 
analysis and subsequent western blot validation indicated that levels of DBN1 
were significantly increased in E1 cells (p = 0.0094, Figure 8). To the best of 
our knowledge, there is currently no evidence in the literature reporting the 
involvement of DBN1 in colorectal cancer, or in any other gastrointestinal 
cancers. As such, we selected DBN1 as a target for further validation in 
clinical colorectal cancer patient tissue samples.    
 
4.1.4. Clinical relevance of DBN1 overexpression in colorectal 
cancer metastasis 
We assessed the levels of DBN1 in primary colorectal cancer tissue sections 
against matched lymph node and liver metastases, and found that the staining 
intensity of DBN1 in the metastatic tissues were significantly higher than in 
the primary tumour (Figure 9). These results suggest that DBN1 may be 
potentially involved in the metastatic progression of colorectal cancer. 
However, the exact mechanism by which DBN1 influences metastasis remains 
unknown.  
 
Interestingly, we observed some indications that DBN1 may be enriched along 
intercellular membranes, which was similar to reports from Peitsch and 
colleagues (2005), who found that DBN1 was enriched along adherens 
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junctions at cell-cell boundaries in epithelial tumour cells. Since DBN1 is an 
actin-binding protein, these results suggest that DBN1 could serve as a 
physical linker between the adherens junctions and the actin cytoskeleton 
network (Peitsch et al., 2005). Cell migration is believed to involve the 
coupling of both cell adhesion and membrane protrusion machineries, and one 
of the ways this could occur is direct coupling through proteins such as 
vinculin (DeMali and Burridge, 2003). Therefore, DBN1 may similarly 
function as a mediator between cell adhesion and protrusion in order to 
promote migration during cancer metastasis. In support of this, there has been 
evidence to show that DBN1 could stabilise cellular adhesions and was co-
expressed with vinculin in neuronal cells (Ikeda et al., 1996). On the other 
hand, DBN1 has also been found to be a binding partner of the gap junction 
protein connexin-43 as well, indicating that DBN1 could be alternatively 
involved in reorganisation of the actin cytoskeleton in response to external 
stimuli (Butkevich et al., 2004). However, the exact mechanism by which 
DBN1 contributes to colorectal cancer metastasis will have to be explored in 









Using an iTRAQ-based comparison between the intracellular protein profiles 
of HCT-116 and E1 cells, we identified DBN1, a neuronal actin-binding 
protein, which was overexpressed in the metastatic-derived E1 cells. We 
further showed that DBN1 levels were significantly increased in lymph node 
and liver metastasis tissues, as compared to primary colon adenocarcinoma 
tissues, indicating the clinical relevance of DBN1 overexpression in colorectal 
cancer metastasis. Our findings represent the first time that DBN1 has been 
shown to be involved in colorectal cancer metastasis. Taking all the evidence 
in the literature in hand, DBN1 is highly likely to be an important player in the 
metastatic progression. Whether DBN1 may have a direct or indirect effect on 
cell motility in colorectal cancer remains unknown and definitely warrants 
























4.2. Part Two. Comparative analysis of the HCT-116 and E1 














The cancer secretome is a highly valuable resource for identification of 
serological biomarkers, since secreted proteins are highly likely of entering the 
blood circulation. Therefore, by comparing between the CM samples collected 
from HCT-116 and E1 cells, we hoped to identify proteins that were 
differentially secreted in E1 cells, which could be translated into potential 
serological biomarkers for colorectal cancer prognosis and disease monitoring. 
By combining an iTRAQ analysis of HCT-116 and E1 CM samples, with a 
large-scale targeted quantitative verification using SWATH-MS acquisition, 
we identified a total of 25 differentially secreted proteins in the E1 secretome. 
Majority of these differentially secreted proteins appeared to be involved in 
processes such as signal transduction, adhesion and migration, as well as 
protein processing and post-translational modifications 
 
4.2.1. Dysregulation of secreted proteins involved in signalling 
The interaction between the tumour cells and their extracellular environment is 
critical in order to create favourable conditions for tumour progression and 
metastasis. This interaction is mediated by a variety of secreted proteins, 
which serve as signalling molecules to transmit information in both autocrine 
and paracrine fashions (Karagiannis et al., 2010). Therefore, it is expected that 
a large majority of secreted proteins that were dysregulated in the E1 
secretome would be involved in signalling. One of these proteins was a well-
known oversecreted protein in colorectal cancer, known as 




GDF15 has a plethora of roles in many physiological processes, and is also 
known by many other names, such as macrophage inhibitory cytokine 1 
(MIC1) and non-steroidal anti-inflammatory drug (NSAID) activated gene 1 
(NAG1). GDF15 belongs to the transforming growth factor-β (TGF-β) 
superfamily, and is involved in mediating cellular responses to stress, 
inflammation, tissue repair, and may also be an anti-apoptotic and potent 
survival factor (Mimeault and Batra, 2010). Considering these, it is hardly a 
surprise to find that elevation of GDF15 expression has been observed in a 
wide variety of cancers, including brain, lung, thyroid, breast and prostate 
among many others (reviewed in Mimeault and Batra, 2010).  
 
In our iTRAQ analysis of the HCT-116 and E1 secretomes, we observed that 
levels of secreted GDF15 were higher in the CM of E1 cells, and verified this 
using both SWATH-MS and western blot (Figure 14A). Our observations 
were consistent with the study performed by Xue and colleagues (2010), who 
also observed the oversecretion of GDF15 in the CM of the lymph node 
metastatic SW620 cell line. Furthermore, increased levels of GDF15 in both 
tissue and serum of colorectal cancer patients have been observed in multiple 
studies, and can be correlated with disease stage, recurrence and metastasis 
(Barderas et al., 2013; Brown et al., 2003; Wallin et al., 2011; Xue et al., 
2010).  
 
However, current knowledge on GDF15 appears to suggest a paradoxical 
functional role in colorectal cancer. In contrary to the elevation of GDF15 in 
both patient tissue and serum samples, in vitro studies in colorectal cancer 
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cells seem to indicate that GDF15 may be tumour suppressive instead. In 
HCT-116 cells, elevation of GDF15 expression induced by NSAIDs resulted 
in apoptosis and reduced tumourigenicity in tumour xenografts (Baek et al., 
2001). Moreover, this induction of GDF15 expression can similarly be 
observed using a large variety of anti-tumourigenic dietary compounds 
(Bottone et al., 2002; Ko and Auyeung, 2013; Shin et al., 2012; Wilson et al., 
2003; Yang et al., 2014; Zhong et al., 2010). Ironically, the pro-tumourigenic 
activity of GDF15 is also supported by experimental evidence, albeit in other 
cancers. For instance, silencing of GDF15 inhibits melanoma growth in 
xenografts (Boyle et al., 2009), while overexpression of GDF15 results in 
enhanced metastasis in both pancreatic and gastric cancer cells (Lee et al., 
2003; Senapati et al., 2010). In an attempt to reconcile the contradictory data 
from both of the factions, Wang and colleagues (2013) suggested that the 
elevation of GDF15 in the serum is a response to stress signals produced as 
GDF15-resistant tumour cells proliferate in the developing cancer. Whether 
this may be true or not remains to be explored. However, regardless of the 
functional role that GDF15 may play, there is still very strong evidence to 
show that GDF15 is a highly promising serological biomarker for colorectal 
cancer prognosis and disease monitoring.     
 
4.2.2. Differential secretion of proteins involved in adhesion and 
migration 
During metastasis, the tumour cells must adhere to, interact with and degrade 
the various components of the basement membrane and the extracellular 
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matrix (ECM). In order to do so, the tumour cells would have to interfere with 
the release of a class of proteins known as matricellular proteins which, 
though non-structural by nature, are able to define and influence the 
composition of the ECM (Bornstein and Sage, 2002). In addition, degradation 
of the ECM is tightly controlled by secreted proteases, which are inevitably 
dysregulated as well in order for the tumour cells to invade into surrounding 
tissues and enter the circulation (Berger, 2002). Therefore, in this section, we 
will examine two such proteins that were shown to be oversecreted in the E1 
secretome: secreted protein acidic and rich in cysteine (SPARC), and serpin 
peptidase inhibitor, clade E member 1 (SERPINE1). 
 
SPARC, also known as osteonectin and BMP-40, is a multifunctional secreted 
protein that has a highly controversial role in cancer. Although SPARC mainly 
functions as a matricellular protein by binding to ECM proteins and regulating 
ECM reorganisation, it is also considered to be involved in signalling. This is 
because SPARC is known to be able to directly and indirectly influence 
several growth factor signalling pathways, such as the fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF) and TGF-β pathways (reviewed in Arnold and Brekken, 2009). 
Therefore, since SPARC is poised to influence multiple cancer hallmarks, 
including angiogenesis, migration, proliferation and survival, it is easily 
foreseen that perturbation of SPARC expression would be frequently observed 




The data from our iTRAQ analysis indicated that SPARC was oversecreted in 
the CM of E1 cells, and this was further confirmed using SWATH-MS and 
western blot (Figure 14B). This would imply that SPARC may play a role in 
colorectal cancer progression and metastasis. However, similar to GDF15 that 
was discussed earlier, SPARC also appears to have contradictory roles in 
cancer. In many different kinds of cancers, including cancers in the brain, 
breast, bladder, colon, lung, liver, pancreas and prostate, there are conflicting 
reports on whether SPARC is a tumour promoter or suppressor in cancer 
(reviewed in Arnold and Brekken, 2009). In colorectal cancer, SPARC was 
first reported by Porter and colleagues (1995) to exhibit positive 
immunoreactivity in patient tissue sections. Using techniques including 
microarrays, western blot, northern blot, quantitative real-time PCR and IHC, 
others have also similarly shown that SPARC expression in the peritumour 
stroma was stronger than in tumour cells, while there was usually little or no 
SPARC expression in normal cells or their surrounding stroma (Chew et al., 
2011; Kim et al., 2013; Madoz-Gurpide et al., 2006; Porte et al., 1995; 
Takemasa et al., 2001; Viana Lde et al., 2013; Wiese et al., 2007). Increased 
SPARC expression could also be correlated to metastasis (Porte et al., 1995) 
and poorer patient survival (Kim et al., 2013). In addition, there are some 
studies which have used in vitro or mouse models to illustrate that SPARC 
could be a tumour promoter. Deficiency of SPARC in mice positive for 
multiple intestinal neoplasia appeared to suppress adenoma formation 
(Sansom et al., 2007), while the absence of the tumour suppressor Smad4 in 




On the other hand, there are other studies reporting that elevation of SPARC 
levels showed either no correlation to staging (Viana Lde et al., 2013), or 
could be associated with better disease outcome and survival (Chew et al., 
2011; Liang et al., 2010). Lower stromal SPARC expression appeared to be 
associated with lymph node invasion and recurrence (Yoshimura et al., 2011), 
and the SPARC promoter region was found to be hypermethylated in various 
colorectal cancer cell lines and patient tissue samples (Cheetham et al., 2008; 
Yang et al., 2007). SPARC expression was also reportedly down-regulated in 
chemoresistant MIP101 colon cancer cells, and the re-expression of SPARC 
restored chemosensitivity and led to tumour regression in xenografts (Tai et al., 
2005). Further studies on MIP101 cells revealed that the chemosensitivity 
induced by SPARC could be enhanced by vitamin D (Taghizadeh, 2007), and 
was dependent on p53 and caspase 8 (Chan et al., 2010; Rahman et al., 2011; 
Tang and Tai, 2007).  
 
However, it may be important to note that the above-mentioned functional 
studies were mainly focused on intracellular SPARC, and that all of the 
studies were performed on a single cell line model. Therefore, given that it is 
mainly the secreted form of SPARC that is elevated during colorectal cancer 
progression, it is likely that secreted SPARC may play a completely different 
role as compared to its intracellular counterpart. Furthermore, since the 
oversecretion of SPARC was one of the highest that we observed in the E1 
secretome, SPARC holds very high promise as a potential serological 
biomarker for colorectal cancer, since SPARC has already been detected in 
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human plasma and serum using mass spectrometry methods (Nanjappa et al., 
2014). 
 
SERPINE1, or usually known as plasminogen activator inhibitor-1 (PAI-1), is 
part of the plasminogen activator system (PAS), which is a well-known 
extracellular protease system involved in invasion and metastasis (Berger, 
2002). The central member of the PAS is plasmin, an extracellular serine 
protease which can degrade, either directly or indirectly, a broad range of 
substrates including fibrin, fibrinogen and other ECM proteins such as laminin 
and fibronectin. The precursor of active plasmin is plasminogen, which is 
activated by urokinase-type plasminogen activator (uPA). Moreover, the 
activation of plasmin can be enhanced by the binding of uPA to its receptor 
(uPAR). Regulation of the PAS is controlled by SERPINE1, which inhibits 
uPA by forming an enzymatically inactive complex with uPA and uPAR. The 
resulting complex would then be internalised through endocytosis (reviewed 
in McMahon and Kwaan, 2008).   
 
The PAS has been implicated in a wide range of metastasis-associated 
processes, including migration and invasion. When the uPA-uPAR complex 
activates plasmin, this in turn activates matrix metalloproteases, which result 
in degradation of the ECM, thus releasing the cell from its adhesion site. 
Furthermore, since the activation of plasmin is enhanced when uPA is bound 
to uPAR, the location of uPAR on the cell surface would determine the 
direction of the migration (Burridge et al., 1988; McMahon and Kwaan, 2008). 
On the other hand, SERPINE1 has a high affinity for an ECM protein known 
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as vitronection, and the association of SERPINE1 and vitronectin serves to 
stabilise SERPINE1 (Berger, 2002). Moreover, this interaction is also 
involved in the internalisation of the SERPINE1-uPA-uPAR complex through 
endocytosis, which promotes cell adhesion and thereby allowing for 
propulsion (McMahon and Kwaan, 2008; Nykjaer et al., 1997).  
 
In addition to its role in migration and invasion, SERPINE1 may be involved 
in promoting proliferation as well. When exogenous SERPINE1 was 
introduced to tumour cells in vitro, this resulted in inhibition of both 
spontaneous and induced apoptosis (Kwaan et al., 2000). Given the 
importance of SERPINE1 in these metastasis-related processes, we were 
hardly surprised to observe that SERPINE1 was oversecreted in the E1 
secretome in the iTRAQ analysis, and this was verified in SWATH-MS and 
western blot analyses (Figure 14C). This finding was consistent with previous 
studies in the literature, where increased SERPINE1 expression has been 
observed in colorectal cancer tissues as compared to controls, and can also be 
correlated to disease staging and metastasis (Herszenyi et al., 1999; Illemann 
et al., 2009; Markl et al., 2010; Sakakibara et al., 2005). SERPINE1 serum or 
plasma levels has also been reported to be able to distinguish between 
colorectal cancer patients from healthy controls, as well as discriminate for 
different disease staging and post-operative recurrence (Herszenyi et al., 2008; 
Yamada et al., 2010).    
 
Although SERPINE1 may appear to be a highly promising serological 
biomarker for colorectal cancer detection, prognosis and monitoring, it is 
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important to note that the time of collection for the patient blood samples may 
be a potential confounding factor in analysis of SERPINE1 levels. The 
SERPINE1 gene is known to be under circadian control and SERPINE1 levels 
in the blood have been shown to be increased in the mornings (Oishi, 2009). 
Recently, a study by Mazzoccoli and colleagues (2012) investigated the 
mRNA levels of SERPINE1 together with ARNTL2, which is a circadian gene 
that directly activates SERPINE1 transcription, in colorectal cancer tissue 
samples. Their results show that both SERPINE1 and ARNTL2 expression 
were increased in colorectal cancer, and could be associated with aggressive 
traits such as lymph node involvement and microsatellite instability. Therefore, 
this is an indication that perhaps more studies are needed to examine the 
fluctuations of serum/plasma SERPINE1 levels in colorectal cancer patients, 
before SERPINE1 can be translated for clinical use as a biomarker. 
 
4.2.3. Differential secretion of proteins involved in post-translational 
modifications 
Many secreted proteins would undergo some form of post-translational 
modification during their synthesis process. This is particularly so for proteins 
that are secreted through the classical secretory pathway, which are often 
glycosylated. However, the proteins that are involved in post-translational 
modifications would most often be localised in the endoplasmic reticulum or 
the Golgi apparatus. It was therefore rather unexpected to observe the 
oversecretion of two such proteins, procollagen-lysine, 2-oxoglutarate 5-
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dioxygenase 3 (PLOD3) and mannosidase, alpha class 1A, member 1 
(MAN1A1), in the E1 secretome. 
 
PLOD3, or more commonly known as lysyl hydroxylase 3 (LH3), is a 
multifunctional enzyme that possesses lysyl hydroxlase, hydroxylysl 
galactosyltransferase, and galactosylhydroxylysl glucosyltransferase (GGT) 
activities (Risteli et al., 2009). In corroboration with our results, PLOD3 has 
been shown to be present in the CM of several cell lines (Salo et al., 2006). 
The authors also detected GGT activity in mouse and human serum, 
suggesting that PLOD3 could possibly be secreted in vivo as well. Although 
the PLOD3 has been recently shown to be oversecreted in the CM of 
pancreatic cancer cell lines (Schiarea et al., 2010), there is currently no 
evidence of PLOD3 oversecretion in colorectal cancer. 
 
The data from our iTRAQ analysis indicated that PLOD3 was oversecreted in 
the E1 secretome, and the same trend was observed in both SWATH-MS and 
western blot analyses (Figure 14D). This suggested that PLOD3 may possibly 
have some role in tumour progression. Indeed, the glycosyltransferase 
activities of PLOD3 has been shown to be important for proliferation and cell 
viability, as cells treated with glycosyltransferase-deficient PLOD3 fragments 
showed arrest in cell growth and eventual lethality (Wang et al., 2009). 
Moreover, there is also evidence indicating that PLOD3 may be involved in 
the deposition and remodelling of the ECM (Risteli et al., 2009; Salo et al., 
2006), of which the latter is a crucial process during metastasis. In addition, 
since PLOD3 has already been detected in human serum, it could be a 
112 
 
promising potential serological biomarker for colorectal cancer metastasis and 
deserves further validation in clinical samples. 
 
MAN1A1 belongs to the family of class I α-mannosidases, which are enzymes 
that cleave α-1,2-mannose residues from oligosaccharide chains on proteins 
(Howard et al., 1997; Lal et al., 1998). MAN1A1 is a type II membrane 
enzyme localised to the Golgi, and is responsible for processing Man8-
9GlcNAc2 to yield Man5GlcNAc2, which is essential for the formation of 
complex and hybrid N-glycans (Herscovics, 1999; Kornfeld and Kornfeld, 
1985). However, a secreted form of MAN1A1 is suspected to exist, as an 
enzyme with class 1 α-1,2-mannosidase activity has been previously detected 
in human serum (Porwoll et al., 1999). Furthermore, MAN1A1 has also been 
recently detected in human plasma using mass spectrometric methods 
(Nanjappa et al., 2014). To the best of our knowledge, there is currently no 
evidence of the involvement of MAN1A1 in any cancer.  
 
The activity of MAN1A1 in modifying cell surface N-glycans has been shown 
to have some influence on natural killer (NK) cell-mediated lysis (Ahrens, 
1993). K-562 cells treated with kifunensine, an inhibitor of class I α-
mannosidases, were shown to accumulate greater amounts of high mannose-
type N-linked Man9GlcNAc2 glycans on the cell surface. This was confirmed 
by the observation that the treated cells had increased binding to Con A, which 
has an affinity for high mannose-type N-linked glycans. More importantly, the 
accumulation of Man9GlcNAc2 glycans resulted in increased binding with NK 
cells and an increase in cell lysis by NK cells. Since NK cells are known to 
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express receptors that show sequence similarities to lectin (Giorda et al., 1990; 
Houchins et al., 1991; Yokoyama et al., 1990) which can interact with N-
glycans (Higai et al., 2011), it may be possible that the high mannose type 
Man9GlcNAc2 oligosaccharides could be recognised by lectin-like receptors, 
which in turn can mediate NK cell-dependent cytotoxicity. More recently, 
kifunensine treatments on T-cells were also shown to be able to reduce the 
activation threshold of naive T-cells (Gebuhr et al., 2011). This could indicate 
that the complex N-glycans generated by MAN1A1 may have some inhibitory 
effects on the activation of naive T-cells.  
 
Since we found that MAN1A1 was oversecreted in the CM of E1 cells, an 
observation which was confirmed by both SWATH-MS and western blot 
(Figure 14E), this suggests that MAN1A1 may be involved in the colorectal 
cancer metastatic cascade. One of the most important steps in the metastatic 
cascade is the ability of tumour cells to evade the host immune cells during 
circulation. Considering that the activity of MAN1A1 has some influence on 
the immune response, it could be likely that MAN1A1 is secreted by 
metastatic cells as a means to evade immune detection in the blood circulation. 
Moreover, since MAN1A1 has also been detected in both human serum and 
plasma, it may be worthwhile to pursue the possibility of using MAN1A1 as a 







4.2.4. Limitations in clinical validation of target proteins 
One of the major bottlenecks in translating from biomarker discovery studies 
to the clinic is the validation of the potential biomarkers in clinical samples. 
Although there are many biomarker discovery studies published regularly each 
year, few of the reported candidates arrive to the clinic. One likely possibility 
could be the unavailability of suitable antibodies for clinical assays. 
Unfortunately, we were faced with the same predicament in our study as well. 
Although a number of promising and potentially novel biomarker candidates, 
such as PLOD3 and MAN1A1, were identified, we were unable to further 
validate these proteins in colorectal cancer patient samples because of the 
unavailability of suitable ELISA kits. To overcome this, MS-based 
alternatives to ELISA may be a possible option, and this will be further 
discussed later in the section on future work. 
 
4.2.5. Summary 
In the second part of this study, we showed that the HFC system was indeed 
an attractive alternative for preparation of CM samples, as it effectively 
concentrates secreted proteins in a smaller volume and also provides better 
culture conditions for the cells. Using an iTRAQ-based comparative analysis 
of the CM samples collected from HCT-116 and E1 cells, we observed that 38 
proteins were differentially secreted in E1 cells as compared to HCT-116. In 
addition, we also showed that the SWATH-MS technology could be a viable 
option for large-scale verification of iTRAQ data. Using SWATH-MS 
acquisition as an approach to perform SRM-like targeted quantitative analysis 
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on the 38 differentially secreted proteins in E1, we found that 25 of these were 
corroborated by the SWATH-MS analysis. Majority of these 25 differentially 
secreted proteins in E1 were found to be involved in processes such as 
signalling, cell adhesion and migration, as well as protein PTM. We validated 
the oversecretion of well-known proteins in colorectal cancer, such as GDF15, 
SPARC and SERPINE1, and also potentially novel secreted proteins, such as 
PLOD3 and MAN1A1, using western blot. However, we were unable to 
advance any further to perform clinical validation as there were no suitable 





























4.3. Part Three. SWATH-MS analysis of the HCT-116 and E1 MLAC-
enriched glycosecretomes: identification of LAMB1 as a potential 














In addition to the several promising candidate proteins that were identified in 
the previous chapter, we were also interested in delving deeper into the HCT-
116 and E1 secretomes to search for more low-abundance secreted proteins. 
Since majority of secreted proteins would be glycosylated in some form, we 
utilised the multi-lectin affinity chromatography (MLAC) approach to enrich 
for secreted glycoproteins from HCT-116 and E1 CM samples. In addition, we 
explored the use of SWATH-MS as a label-free quantitative proteomics 
approach to compare between the HCT-116 and E1 glycosecretomes. A total 
of 149 glycoproteins were identified to be differentially secreted in E1 cells as 
compared to HCT-116, with a large portion of these proteins mapped to 
processes important in metastasis, such as adhesion and ECM organisation, 
signalling, as well as migration and cytoskeletal organisation 
 
4.3.1. Differential secretion of glycoproteins involved in adhesion and 
ECM organisation     
The ECM is not a mere passive bystander but is actively involved in tumour 
progression, including directly promoting proliferation and metastasis, as well 
as influencing the behaviour of stromal cells, and facilitating angiogenesis and 
inflammation (Lu et al., 2012). The composition of the ECM can be controlled 
by matricellular proteins and proteases which are secreted by the tumour cells 
and some of which have been discussed earlier in section 4.2.2. However, the 
tumour cells can also directly affect the composition of the ECM by 
expressing and secreting ECM proteins (Sherman-Baust et al., 2003). Since 
many ECM proteins are glycoproteins (Gu et al., 2012), it was entirely 
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expected that ECM proteins would be among the majority of the differentially 
secreted proteins in the MLAC-enriched glyco-secretome of E1 as compared 
to HCT-116. As such, in this section, we will examine more closely two such 
proteins which were oversecreted in E1 cells: collagen type VI, α-2 (COL6A2) 
and laminin, β-1 (LAMB1). 
 
COL6A2 is a polypeptide chain that, together with COL6A1 and COL6A3, 
comprises the ECM protein, collagen VI. Collagen VI is widely distributed 
across various tissues, and is responsible for forming a network of beaded 
microfilaments that interacts with other ECM proteins and provide structural 
support for cells. In addition to its structural role, collagen VI has also been 
shown to be able to affect apoptosis, autophagy, proliferation, angiogenesis, 
and inflammation (reviewed in Chen et al., 2013). Therefore, considering the 
involvement of collagen VI in these processes, it is not unexpected to find that 
increased expression of collagen VI has been observed in several cancer types, 
including breast cancer (Motrescu et al., 2008), ovarian cancer (Sherman-
Baust et al., 2003), melanomas (Burchardt et al., 2003), gliobastomas (Paulus 
et al., 1988) and juvenile angiofibromas (Gramann et al., 2009).  
 
In our SWATH-MS analysis, we observed that COL6A2 was oversecreted in 
E1 cells, and this was confirmed using western blot (Figure 18A). Although 
there is currently no evidence of COL6A2 in colorectal cancer metastasis, 
similar findings have already been observed in other cancers. For instance, the 
COL6A2 gene has been reported to be part of a ten-gene panel that was 
commonly up-regulated in metastatic head and neck square cell carcinoma as 
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compared to lung squamous cell carcinoma (Vachani et al., 2007). Similarly, 
COL6A2 was identified to be a part of a ten-gene signature which was 
associated with poor overall survival in high-grade serous ovarian cancer 
patients (Cheon et al., 2014). Using quantitative real-time PCR, Liu and 
colleagues (Liu et al., 2010b) also found that expression levels of COL6A2 
was up-regulated in primary and metastatic gliomas. These findings indicate 
that COL6A2 might have a role to play in cancer metastasis. Indeed, collagen 
VI has been shown to be able to promote cell process adhesion and extension 
in glioblastoma cells (Han and Daniel, 1995), and collagen VI treatment in 
malignant lung epithelial carcinoma cells was also found to enhance cell 
motility to a considerable extent (Wright et al., 2008). More importantly, 
collagen VI levels were reportedly increased in serum samples from patients 
with melanoma, although there was no significance between Stage IV and I/II 
patients (Burchardt et al., 2003). Since there is already evidence of the 
presence of COL6A2 in the human plasma (Nanjappa et al., 2014), it might be 
interesting to pursue the validation of COL6A2 as a potential biomarker in 
colorectal cancer metastasis.  
 
Laminins are the most abundant non-collagenous glycoproteins which 
comprise the basement membrane, and LAMB1 is one of the three β-subunits 
which assemble together with various α- and γ-subunits to form a variety of 
heterotrimeric laminin isoforms (Aumailley and Smyth, 1998). More than 14 
laminin isoforms have been identified, and each have different tissue 
distributions and functions (Givant-Horwitz et al., 2005). For instance, 
laminin-2 has been found to be localised to the basement membrane in 
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muscles, while laminins-8 and -10 have been described mostly at the 
endothelial basement membranes (Engbring and Kleinman, 2003). Laminins 
have also been implicated in many cancer-related processes, including 
proliferation, adhesion, migration, invasion and angiogenesis, and these are 
typically mediated through integrin signalling (reviewed in Engbring and 
Kleinman, 2003; Givant-Horwitz et al., 2005). 
 
The results of our SWATH-MS analysis indicated that LAMB1 was 
oversecreted in the E1 secretome, and this was confirmed using western blot 
(Figure 18B). Our findings were similar to several reports in the literature, 
where LAMB1 expression has been found to be increased in hepatocellular 
carcinoma tissues (Lim et al., 2002), and co-expressed with keratin-19, a 
hepatic progenitor marker that has been frequently associated with poor 
prognosis hepatocellular carcinomas (Govaere et al., 2014). The LAMB1 gene 
has also been reportedly found to be up-regulated in chemoresistant ovarian 
cancer cell lines (Januchowski et al., 2014), and associated with ulcerative 
colitis, which is known to lead to increased risk of colorectal cancer (UK IBD 
Genetics Consortium et al., 2009). Currently, only Saito and Kameoka (2005) 
has performed an investigation of laminin levels in the serum of colorectal 
cancer patients. However, although not specified in their report, the anti-
laminin enzyme-immunoassay (EIA) kit used in their study appeared to be 
targeted against the laminin γ-1 (LAMC1) chain. Therefore, since there are 
currently no studies on LAMB1 in any colorectal cancer clinical samples, we 





4.3.2. Clinical relevance of LAMB1 elevation in colorectal cancer 
patient serum samples  
Using a commercially available ELISA kit, we observed that the serum levels 
of LAMB1 were significantly higher in colorectal cancer patients as compared 
to healthy controls (Figure 19A). Moreover, serum LAMB1 levels could be 
used to discriminate colorectal cancer patients from healthy controls with a 
sensitivity of 64% and specificity of 96%. This performance was better than 
that of CEA at the typical clinical cut-off value of 5.0 ng/ml, where the 
sensitivity and specificity were 53% and 89% respectively. When LAMB1 and 
CEA were used in combination, the sensitivity was improved to 80%, 
although the specificity was slightly reduced to 92% (Figure 20D). This 
indicated that LAMB1 could be a potential serological biomarker for diagnosis 
of colorectal cancer. 
 
We further analysed the LAMB1 serum levels according to the respective 
Dukes' classification that the 45 colorectal cancer patient samples were 
grouped into, but there was no significant difference between the LAMB1 
levels across the different Duke's stages (Figure 19C). This was similarly 
observed by Saito and Kameoka (2005) as well, when they assessed for 
association between serum LAMC1 levels and patients with different Duke's 
lesions. However, the number of patients in most of the stages in our analysis 
may be too small to be meaningful. Furthermore, as the clinical information 
available to us was only restricted to the Duke's staging, we were unable to 
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assess if LAMB1 could be used as a biomarker for prognosis or disease 
monitoring. To do so, we would require more clinical data on the patients, 
such as whether the serum samples were collected pre- or post-surgical 
resection, occurrence of disease relapse and metastasis, as well as the location 
of the metastases. If these data could be obtained, further analysis to explore 
the prognostic utility of LAMB1 would definitely be warranted in any future 
work. 
 
Although our findings indicated that secreted LAMB1 could have some 
clinical involvement in colorectal cancer metastasis, the exact mechanism 
behind its involvement remains unclear. The YIGSR peptide of LAMB1 has 
been shown to bind to the 67 kDa laminin receptor (LamR), and this 
interaction was found to promote cell adhesion (Massia et al., 1993). 
Subsequent studies have further shown that the LamR may also be involved in 
proliferation (Satoh et al., 1999), angiogenesis (Tanaka et al., 2000), migration 
(Vande Broek et al., 2001), and invasion (Mafune and Ravikumar, 1992). 
Furthermore, overexpression of LamR has been previously shown to be 
associated with colorectal cancer progression and metastasis (Sanjuan et al., 
1996). As such, the oversecretion of LAMB1, in conjunction with the 
overexpression of its receptor LamR, may play an important role in colorectal 





4.3.3.  Summary 
In this third part of the study, we enriched for secreted glycoproteins in HCT-
116 and E1 CM samples using the MLAC approach. Out of the 421 proteins 
identified for quantitative analysis, 96% of these were predicted to be secreted 
proteins and 70% were shown to contain glycosylations, indicating that the 
MLAC enrichment for secreted glycoproteins was largely successful. Using 
SWATH-MS as a label-free quantitative proteomics approach to compare 
between the MLAC-enriched glycosecretomes from HCT-116 and E1, we 
identified LAMB1, a component of the basement membrane laminins, to be 
oversecreted in E1 cells. In addition, we have shown for the first time that 
LAMB1 could be a potential biomarker for colorectal cancer when used in 
conjunction with CEA. However, due to the limited clinical information on the 
patient samples, we were unable to assess further whether serum LAMB1 
levels could be used for disease prognosis or monitoring. In terms of 
functional role, the evidence in the literature appears to indicate that 
extracellular LAMB1 could have an influence on metastatic-related processes 
through its receptor, LamR. However, the reason why the secretion of LAMB1 
is enhanced in metastatic colorectal cancer cells is yet unknown, and more 
work will be required to elucidate the significance of the LAMB1-LamR 
































In our study, we have attempted to address some of the clinical needs in 
colorectal cancer management by using various proteomics approaches. In the 
first part, to uncover novel proteins in colorectal cancer metastasis, we 
performed an iTRAQ-based comparison between the intracellular proteins in 
the HCT-116 cell line and its liver metastatic derivative, E1. We observed that 
DBN1 was overexpressed in E1 cells, as compared to HCT-116, and further 
showed that DBN1 overexpression was clinically relevant in colorectal cancer 
patient tissue samples. We also noticed that DBN1 showed some indication of 
enrichment along cell-cell membrane boundaries, suggesting that DBN1 could 
be involved in physical coupling of the actin cytoskeletal network to adherens 
junction or gap junction complexes. Considering this, potential future studies 
could include investigating whether manipulations of DBN1 expression in 
colorectal cancer cells would affect cell motility, morphology and adhesion. In 
addition, we could also explore the cellular localisation of DBN1 in colorectal 
cancer cells using immunofluorescence and whether it co-localises with actin, 
vinculin or connexin-43. Subsequently, we can confirm whether DBN1 indeed 
binds to these proteins by identifying the interaction partners of DBN1 using 
co-immunoprecipitation. In addition, this would enable us to map the possible 
pathways of the mechanism that DBN1 contributes to colorectal cancer 
metastasis.    
 
In the second part of our study, we showed that the HFC system is an 
appealing and viable alternative for preparation of CM samples. The HFC 
system facilitates CM collection by concentrating secreted proteins in a small 
volume, and also provides better growth conditions for the cells. Subsequently, 
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to identify secreted proteins that could be potential biomarkers for colorectal 
cancer metastasis, we performed another iTRAQ-based comparison between 
the CM samples collected from HCT-116 and E1 cells. Before selecting 
candidate proteins for validation using western blot, we further improved the 
confidence in the list of differentially secreted proteins by performing a large-
scale targeted quantitation verification using SWATH-MS analysis. Sixty-six 
percent of the differentially secreted proteins identified by iTRAQ were 
corroborated by the SWATH-MS analysis, and out of the five proteins 
selected for western blot validation, the differential secretion of all five were 
correctly reported. These findings showed that the SWATH-MS technology 
could be an attractive approach for performing large-scale verification of 
iTRAQ data before selecting any proteins for downstream validation and 
analysis.  
 
Several interesting differentially secreted proteins in E1 were identified, 
including well-known secreted proteins in colorectal cancer such as GDF15, 
SPARC and SERPINE1. Potentially novel secreted proteins involved in 
colorectal cancer metastasis were identified as well, such as PLOD3 and 
MAN1A1. However, due to unavailability of suitable commercial ELISA kits, 
we were unable to further validate the feasibility of PLOD3 and MAN1A1 as 
potential biomarkers in patient serum samples. A possible alternative to 
overcome this in any subsequent studies would be the development of MS-
based techniques, such as SRM assays, to detect and quantify the levels of the 
candidate proteins in clinical samples. Advances in SRM technology have 
been shown to potentially be able to address the problem of antibody 
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availability, as demonstrated recently by Ahn and colleagues (2010), who used 
a targeted LC-MS/MS workflow to validate eight potential breast cancer 
biomarkers in patient plasma samples. Therefore, the use of SRM-based 
assays could become an attractive alternative for ELISAs in the foreseeable 
future, given its multiplexing capability and the continually improving 
sensitivity of the mass spectrometers.  
 
In addition, given the importance of immune evasion during metastasis, it 
would be interesting to examine the function of MAN1A1 in colorectal cancer 
more closely. Since the N-glycan modification activity of MAN1A1 could be 
linked to immune response, it may be possible that MAN1A1 might be 
secreted by metastatic colorectal cancer cells to process high mannose-type N-
glycans on the cell surface to evade immune detection. To investigate this, 
possible future work could include examining if E1 cells elicit a lower NK cell 
response as compared to HCT-116 cells, and subsequently verifying if this 
could be overcome by inhibition of MAN1A1 activity. It would also be 
interesting to compare between the cell surface glycan profiles of HCT-116 
and E1 cells to observe if E1 cell surface is composed of more processed and 
complex N-glycans due to the activity of MAN1A1. 
 
In the third and final part of our study, we decided to probe deeper into the 
HCT-116 and E1 secretomes by performing a MLAC-based enrichment for 
secreted glycoproteins. We also adopted the SWATH-MS technology as a 
label-free quantitative approach to compare between the HCT-116 and E1 
glycosecretomes. We found that LAMB1 was oversecreted in E1 cells, and 
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further validated that serum LAMB1 levels were significantly higher in 
colorectal cancer patients as compared to healthy volunteers. However, due to 
the limited clinical information on the patient samples, we were only able to 
conclude at the moment that LAMB1 could be a potential screening biomarker 
to distinguish between colorectal cancer patients and healthy individuals.  
 
The clinical information available to us at the moment is restricted to only the 
Dukes' staging of the tumour assessed at the moment of surgical resection. 
However, in order to assess whether LAMB1 could be used for prognosis and 
disease monitoring, potential future work could include a prospective study 
where the pre-operative and post-operative LAMB1 levels would be measured 
in the serum, and the patients monitored for any subsequent recurrence and/or 
metastasis. Other possible studies could also include exploring further into the 
MLAC-enriched glycosecretomes from HCT-116 and E1 cells. For instance, 
in our current study, we focused only on secretion level differences between 
proteins which are known to be glycosylated. However, as altered 
glycosylation patterns has been long recognised to be one of the key events in 
cancer progression, the MLAC enrichment may have also captured for 
secreted proteins which are newly-glycosylated or hyper-glycosylated during 
colorectal cancer metastasis. Therefore, it could be meaningful to confirm if 
these secreted proteins are truly glycosylated, and to identify the nature and 
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